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SOMMARIO 
Introduzione: Diete ricche di vegetali sono state ripetutamente associate ad 
un effetto protettivo sul rischio di malattie cardiovascolari. In particolare 
diverse evidenze sottolineano gli effetti della dieta vegetariana e della dieta 
Mediterranea nel ridurre il colesterolo LDL e il colesterolo totale. E’ stato 
ipotizzato che tali effetti siano il risultato di una diminuzione 
dell’assorbimento del colesterolo alimentare e/o di una diminuzione della sua 
sintesi. Inoltre l’ampia variabilità inter individuale nell’effetto della dieta sui 
livelli di colesterolo potrebbe essere collegata ad interazioni tra i geni 
coinvolti nel metabolismo del colesterolo e fattori nutrizionali.  
Scopo ed obiettivi: Nell’ambito del progetto ATHENA (7 PQ) abbiamo 
studiato gli effetti di componenti dietetici, in particolare antocianine e 
polifenoli, su fattori di rischio cardiovascolare e i possibili meccanismi 
molecolari alla base della variabilità interindividuale nella risposta alla dieta.  
Metodi: Abbiamo reclutato 450 volontari apparentemente sani. I dati raccolti 
includono informazioni demografiche, cliniche, nutrizionali, biochimiche e 
genetiche. Il consumo di macro e micronutrienti è stato calcolato tramite 
interviste 24h dietary recall, ripetute almeno due volte in un anno per 
apprezzare variazioni stagionali. I pattern dietetici (onnivoro/vegetariano) 
sono stati riportati dai soggetti reclutati, mentre l’aderenza alla dieta 
mediterranea è stata valutata tramite un questionario. Abbiamo analizzato le 
associazioni tra steroli plasmatici, implicati nell’omeostasi del colesterolo, e 
fattori nutrizionali tramite regressione multiparametrica. Abbiamo esplorato 
la presenza di interazioni Gene*Environment (G*E) in cinque geni candidati 
precedentemente riportati in studi di nutrigenomica o che codificavamo per 
proteine modulate dalla dieta: per LDL (CYP7A1, INSIG2, LPA, PCSK9) e 
per HDL (PON1). Inoltre abbiamo sviluppato uno strumento per la gestione 
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degli studi di nutrigenomica che include una piattaforma web e una mHealth 
app. 
Resultati: Gli individui che assumevano diete ricche di vegetali (vegetariani, 
soggetti con alta aderenza alla dieta Mediterranea e soggetti con alto 
consumo di polifenoli) avevano BMI e pressione sanguinea più bassi degli 
individui con diete povere di vegetali. Nei vegetariani i livelli di colesterolo 
totale ed LDL erano più bassi.  
I fitosteroli erano significativamente aumentati nei soggetti con diete ricche 
di vegetali. Il latosterolo era significativamente diminuito negli individui con 
alta aderenza alla dieta Mediterranea. Il 27-idrossicolesterolo (27-OHC) è 
risultato aumentato in tutti i gruppi con diete ricche di vegetali. Quattro SNP 
indipendenti del gene PON1 modulavano in modo significativo l’effetto delle 
antocianine/polifenoli su fattori di rischio cardiovascolare. Uno SNP di 
PCSK9, già noto per determinare una mutazione funzionale, ha dimostrato 
di essere in significativa interazione con la dieta nel determinare i livelli 
plasmatici di LDL. 
Discussione: Il nostro studio mostra che diete ricche di vegetali aumentano 
il turnover del colesterolo nei tessuti periferici. Questo effetto si potrebbe 
sommare a quelli osservati sull’assunzione e sulla sintesi endogena, 
contribuendo a determinare gli effetti positivi delle diete ricche di vegetali sul 
colesterolo plasmatico. I risultati delle interazioni dei geni PON1 e PCSK9 
con la dieta nel modificare il profilo lipidico necessitano validazione. La 
soluzione mHealth implementata fornisce indicazioni in maniera semi 
automatica, utilizzando output di un sistema di decisione assistita che 
devono essere validati da un professionista della salute prima di essere 
visualizzati dal paziente. Inoltre offre la possibilità di monitorare il paziente e 
di raccogliere in modo semplice i dati sugli stili di vita nell’ambito di studi 
nutrizionali o nutrigenetici.  
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ABSTRACT 
Introduction: Plants-rich diets have been consistently associated with 
protective effects on Cardiovascular Disease (CVD), in particular a significant 
body of evidence underlines the effects of vegetarian diet and Mediterranean 
diets on LDL and total cholesterol levels. It has been postulated that 
modifications are the effect of decreased dietary absorption of cholesterol 
and/or decreased synthesis. In addition the large individual variability in the 
response to diet-induced changes in cholesterol levels could be related to 
interaction between genes involved in cholesterol metabolism and dietary 
factors. 
Aim and objectives: In the context of the ATHENA study (7FP), we explored 
the effects of dietary components, particularly anthocyanins and 
polyphenols, on CVD risk factors and the possible molecular mechanisms 
underlying inter-individuals variability in the response to diet. 
Methods: We recruited 450 apparently healthy volunteers. We collected 
demographic, clinical, dietary, biochemical and genetic data. Macro and 
micro nutrients intake was estimated through 24 hour dietary interview 
repeated at least twice to get seasonal variations. Overall dietary patterns 
(vegetarian/omnivore) were self-reported while adherence to Mediterranean 
diet was evaluated through a questionnaire. We analyzed the association 
between non-cholesterol sterols which are implicated in cholesterol 
homeostasis and dietary components using multiparametric regression 
models. We explored Gene*Environment (G*E) interactions, on five 
candidate genes previously reported in nutrigenomic studies or encoding 
proteins modulated by diet: for LDL (CYP7A1, INSIG2, LPA, PCSK9) and for 
HDL (PON1). In addition we developed a tool to manage nutrigenomic 
studies that includes a web-platform and a mHealth app. 
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Results: Individuals with plants-rich diets (i.e. vegetarians, those with high 
adherence to Mediterranean diet and those with high polyphenols intake) had 
lower BMI and lower blood pressure compared to individuals with low-plants 
diets. Vegetarians showed decreased total cholesterol and LDL levels. 
Phytosterols were significantly increased in plants-rich diets. Lathosterol was 
significantly decreased in relation to adherence to Mediterranean diet. 27-
hydroxycholesterol (27OHC) levels resulted increased in all plants-rich diets. 
Four independent SNPs of PON1 were shown to modulate the activity of 
polyphenols/anthocyanins on CVD risk factors. A SNP of PCSK9, already 
reported in relation to a “gain of function” mutation showed interaction with 
overall diet in determining LDL plasma levels. 
Discussion: Our study showed that plant-rich diets increase the cholesterol 
turnover in the peripheral tissues. This mechanism, combined with already 
reported modifications in the absorption of cholesterol and decrease de novo 
synthesis, can contribute to the widely recognized beneficial effects of plant-
rich diets on cholesterol levels. The results reported for G*E interactions of 
PON1 and PCSK9 genes with dietary factors in modifying the lipid profile 
warrant replication. The mHealth solution implemented, delivering semi-
automatic suggestions, based on the outputs of a Decision Support System 
than needs to be validated by healthcare professionals before being 
displayed at patient side, offers the possibility to track the patient lifestyles 
and to collect valuable information for nutritional and nutrigenetic studies. 
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1 INTRODUCTION 
1.1 Concept 
Cardiovascular diseases (CVD) are the first cause of death worldwide, 
determining 17.9 millions of deaths per year. Coronary heart disease and 
stroke account for more than 85% of these deaths 1. 
Two large case control studies INTERHEART 2 and INTERSTROKE 3, 
that collected data from 52 different countries all over the world, indicate that 
up to 90% of the risk of developing acute myocardial infarction and 90.7% of 
the risk of developing acute stroke can be accounted for by modifiable risk 
factors (such as smoking, hypertension, diabetes, waist/hip ratio, psycho-
social factors, physical activity, alcohol consumption and fruit and vegetable 
consumption).  
Such evidences guided the definition of recent guidelines for cardiovascular 
disease management. 
According to the 2016 European Guidelines on Cardiovascular Disease 
Prevention: “Prevention should be delivered (i) at the general population level 
by promoting healthy lifestyle behavior and (ii) at the individual level, i.e. in 
those subjects at moderate to high risk of CVD or patients with established 
CVD, by tackling unhealthy lifestyles (e.g. poor-quality diet, physical 
inactivity, smoking) and by optimizing risk” 4. 
In addition, International clinical guidelines recommend that patients without 
prior CVD have their CVD risk estimated by risk scores, to inform the intensity 
of risk factor management. The risk of experiencing a CVD over a certain 
time period (typically 5-10 years) is usually calculated using risk scores 
derived from the Framingham risk score (from the first publication by 
Anderson et al, 5 to more recent updates). Existing risk score does not 
include any lifestyle risk factor apart from smoke. The SCORE - Systematic 
Coronary Risk Evaluation- is currently the most widely accepted risk score 
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tool in Europe. It is based on national data sets from European countries, 
totaling around 250.000 people 6. 
A substantial body of evidence implicated several aspects of diet with the 
occurrence of CVD. Studied dietary factors include nutrients (macronutrients, 
micronutrients, etc.) foods and overall dietary patterns (e.g. Mediterranean 
Diet 7). Several evidences from high risk groups (e.g. diabetics) support the 
use of dietary and more in general lifestyle interventions. Fewer studies are 
conducted on “apparently healthy” individuals, as in this population longer 
follow up periods are needed to observe changes in clinical outcomes.  
There is wide consensus in the scientific community and among policy 
makers on the need to develop targeted lifestyle interventions, stratified 
according to the patient risk. Among those, personalized nutrition 
interventions were proposed, taking advantage of the increasing interest of 
citizens in participating actively to their prevention. Current barriers to the 
use of personalized nutrition include: lack of validation (often the biological 
meaning is unclear) and lack of acceptability by medical community.  
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1.2 State of the art on CVD prevention through dietary interventions 
1.2.1 Diet as risk factor for CVD 
The risk of CVD is strongly associated with socio-behavioral risk factors: 
smoking, insufficient physical activity and unhealthy diet. The role of diet in 
health promotion was already recognized in the 5th Century BC, as witnessed 
by the Plato, which introduces the concept of “healthy diet” in his dialogues. 
However we became aware of the actual relevance of diet in disease 
prevention and health promotion only in the last decades. 
A number of epidemiological studies, systematic reviews and meta-analyses 
indicated that healthy diets (such as vegetarian or vegan diets 8) are 
associated to a reduced risk of CVD (but also of cancer and 
neurodegenerative disorders). A recent review considering 86 cross-
sectional studies, reported that vegetarian diet is consistently associated with 
an improved lipid profile in particular with a reduction of Body Mass Index 
(BMI), Low Density Lipoprotein (LDL) cholesterol and total cholesterol 8. 
A well-studied example of healthy dietary pattern is the Mediterranean diet, 
typical of southern European countries, which includes several daily servings 
of fruit/vegetables, whole-grain cereals, legumes, accompanied by wine in 
moderation and less frequently meat and dairy products. According with the 
meta-analysis conducted by Sofi et al, including12 studies, for a total of 
1.574.299 subjects, high adherence to Mediterranean Diet resulted in 9% 
decrease in CVD mortality 9. In Spain a large interventional trial (N=7,447) 
demonstrated that Mediterranean diet, supplemented with olive oil or nuts, 
reduced the incidence of major cardiovascular events compared to control 
diet in persons with high cardiovascular risk 10. 
Few studies analyzed the effects of dietary athocyanins on CVD risk factors 
in an ecological context, despite the increasing number of interventional 
studies supporting their role in influencing lipid profile and the strong 
evidences obtained in animal and in vitro studies 11.  
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Anthocyanins are red-blue-violet pigments present in many fruits, vegetables 
and flowers that belong to the large class of polyphenols. Polyphenols 
include diverse molecules: while they all serve as antioxidants, they are not 
equally effective, they differ widely in their concentrations in different foods, 
they differ in their bioavailability and their metabolism by the microflora of the 
gastrointestinal tract 12. The most “famous” polyphenol is resveratrol, 
responsible of the “French Paradox”, but other well-known classes of 
polyphenols include catechins and flavonoids (mainly isoflavones from soy), 
which have been widely studied. Anthocyanins are generally widely available 
in traditional diets such as the Mediterranean diet. Despite the long history 
of consumption of anthocyanins, particularly in traditional diets, there was 
relatively little attention focused on this class of polyphenols until recently. 
Preclinical studies within the FLORA project, co-funded by the EC under the 
6FP, demonstrated that dietary anthocyanins can offer cardio-protection, 
reduce the progression of cancer and limit weight gain in animals fed a high 
fat diet. The bioavailability and the beneficial effects of dietary anthocyanins 
depend largely from the chemical structure of each anthocyanin and from the 
food matrix 13. 
ATHENA “AnThocyanin and polyphenol bioactives for Health Enhancement 
through Nutritional Advancement”, an EU funded collaborative project (Grant 
Agreement 245121), aimed to explore the role of anthocyanins and 
polyphenols in health enhancement. The project has taken the advantage of 
the multidisciplinary interactions among and the complementary expertise of 
biotechnologists, human and plant geneticists, nutritionists and clinical 
epidemiologists. In particular, one of the aims of the project was to determine 
whether anthocyanin/polyphenols rich diets can offer protection against CVD 
in humans. This goal has been addressed through an observational study on 
500 healthy Italian subjects, divided according to their dietary habits in 
omnivores and vegetarians.  
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Postulated disease-preventive mechanisms of rich-plants diets are related to 
biologically active compounds (i.e. vitamins, minerals, fiber etc.) that are 
highly represented in fruits and vegetables and that impact on the following 
processes.  
Antioxidant activity: vegetables and fruits contain several micronutrients 
which have antioxidant properties. For long times studies have focused on 
vitamins with antioxidant properties (vitamins C and E and carotenoids), but 
more recently polyphenols are gaining attention, since they show stronger 
antioxidant properties and since they are (collectively) the most represented 
antioxidants in the diet. Some studies indicate that polyphenols exert a direct 
activity, as scavengers of reactive oxygen species and indirect activity, 
stimulating endogenous antioxidant systems 14. 
Decrease of platelet aggregation: Data from studies on garlic and on some 
flavonoids suggest that they may act through inhibition of lypoxygenase and 
cyclooxygenase activity 15. 
Decrease of blood pressure: High blood pressure is an important risk factor 
for coronary heart disease and stroke. Sodium intake is a well-known dietary 
determinant of hypertension while the intake of fiber, magnesium and 
potassium with diet is inversely associated with systolic and diastolic blood 
pressure 16. Vegetarian-diets and plants-rich diets such as the DASH 
(“Dietary Approaches to Stop Hypertension”) diet, which are rich in these 
nutrients, were associated to a significant reduction in blood pressure 17-
18. 
Modification of cholesterol metabolism: Animal studies suggest that dietary 
fiber is determinant in reducing cholesterol, through different mechanisms, 
which are partially source-specific.  
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On the basis of the effects observed in animals and humans, possible 
mechanisms implicated in cholesterol reduction include: “1) increased 
excretion of fecal bile acids and neutral steroids, 2) altered ratios of primary 
to secondary bile acids”, 3) decreased cholesterol absorption, due to 
competition with other components and to decrease in high-cholesterol-
containing foods in the diet 15.  
In addition, a vegetable-rich diet could affect lipid profile since it reduces BMI. 
Despite the fact that the possible mechanism of action are not fully 
elucidated, the evidences on the beneficial effects of plants-rich diets on 
cholesterol levels are so consistent that most Scientific Societies recommend 
dietary changes as first-line therapy for dyslipidemia, because they are safe 
and inexpensive. 
The relation between a healthy diet and endothelial function has been 
investigated by van Bussell et al, in a longitudinal study on 557 subjects of 
the CODAM (“Cohort on Diabetes and Atherosclerosis Maastricht”) Study, at 
increased risk of CVD. This study demonstrated that a higher consumption 
of some foods, i.e. fish, but not vegetables, dairy products and meat were 
associated with endothelial dysfunction scores 19. 
Intima Media Thickness (IMT) of the carotid artery in adults, is a well-
established noninvasive measure of the extent and severity of subclinical 
atherosclerosis, associated to endothelial dysfunction. A recent systematic 
review indicates that the current evidence on the effects of specific 
micronutrient consumption and carotid IMT is largely inconclusive 20. 
 
These evidences reinforce the concept of a “common soil” for most 
cardiovascular disease, which is supported by the observation that all these 
diseases share common risk factors, such as smoking, unhealthy eating, 
physical inactivity, and, even more importantly, predisposing conditions, 
such as obesity, diabetes, metabolic syndrome, dyslipidemia.  
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1.2.2 Prevention programmes targeting dietary habits 
In 1972 the North Karelia Project was launched in Finland, the Country with 
the highest CVD mortality in the world at the time. North Karelia was chosen 
since it was a County with record CVD events and particularly Coronary 
Heath Disease (CHD) mortality as a result of a diet high in salt and saturated 
fat, and low in vegetables, in addition to high rates of smoking and physical 
inactivity. 
It was the first major community-based project for CVD prevention and 
combined integrated interventions to promote healthier dietary habits, 
exercise patterns and smoking reduction. The three main risk factors that 
were targeted in the prevention programme were: total cholesterol; 
hypertension and smoking. Within 5 years, the project resulted in an 
amazingly rapid decline in CHD mortality: of 17.4% in men and of 11.5% in 
women. Smoking habits did not significantly change in the study period while 
the reduction of hypertension and total cholesterol were significant. In 
particular a 4.1 and 1.2% reduction in serum cholesterol was exhibited in 
men and women, respectively 21. 
 
Preventable risk factors for CVD are now well studied and understood but 
despite the number of supporting evidences, prevention programmes 
targeting dietary habits are still uncommon (“spot”) and their efficacy is very 
variable and very much dependent of the programme characteristics. 
According with WHO Action Plan 2013-2020 the policy measures that should 
be promoted at global level include: 
 “Reduce the level of salt/sodium added to food (prepared or 
processed). 
 Increase availability, affordability and consumption of fruit and 
vegetables. 
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 Reduce saturated fatty acids in food and replace them with 
unsaturated fatty acids. 
 Replace trans-fats with unsaturated fats. 
 Reduce the content of free and added sugars in food and non-
alcoholic beverages. 
 Limit excess calorie intake, reduce portion size and energy density of 
foods.” 
 
On other hand, different strong socio-economic factors steer lifestyle habits 
in an opposite direction. For example, the Mediterranean diet is progressively 
losing its diffusion in those countries of the Mediterranean area where it was 
first described. This is due to marked changes in life styles and working 
conditions, resulting in a drastic reduction in calories consumed in job-related 
activities and in time dedicated to cooking.  
Research on how food environment influences food choices has grown and 
emphasized that our food environment makes it difficult for consumers to 
choose healthy foods, especially when food marketing drives unhealthy 
choices and low nutrient and high calories foods. In addition the last 
economic crisis emphasized the fact that the major ingredients of the 
Mediterranean diet (e.g. fruits, vegetables and fish) may not be affordable for 
the lower socio-economic strata, which is the strata with higher CVD 
incidence. In fact, despite existing evidences and suggestions by WHO, the 
report “The rising cost of a healthy diets” estimates that over the last 30 years 
the relative cost of fresh fruit and vegetables has increased more rapidly than 
other types of foods including fast foods. These trends are particularly 
evident in emerging Countries, but they can be detected also in UK and US 
22. 
Fast foods, rich in fats, sugar and salt, and low in fiber and phytonutrients, 
have invaded European tables. The impact of such “westernization” of diet is 
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stronger in younger generations that are at increased risk of obesity and 
associated complications. In the WHO European Region 30% of 11 years old 
children is overweight or obese and this figures are ten times higher than in 
1979 23. The European Commission implemented different policies to face 
obesity prevention, but the phenomenon does not show decreasing trends.  
 
1.2.3 State of the art on diet and cholesterol metabolism 
1.2.3.1 Overview of cholesterol metabolisms 
Cholesterol is an essential component of human cell membranes and it is the 
precursor of steroid hormones and bile acids. Regulation of cholesterol 
homeostasis is controlled by three main fluxes: intestinal absorption, de novo 
synthesis and catabolism, mainly through bile acid synthesis. Thanks to a 
number of control and feedback mechanisms, cholesterol absorption, de 
novo synthesis and bile acid production are interactive, so that an increased 
absorption through diet is compensated by lower synthesis and increased 
excretion. If such homeostasis is impaired, due to malfunctioning of 
mechanisms regulating cholesterol exchange from plasm to tissues, or 
cholesterol absorption, or de novo synthesis or excretion, plasma cholesterol 
increases.  
Dietary cholesterol enters the small intestine, where absorption occurs24. 
The rate of absorption varies from 29.0 to 80.1% in healthy subjects 25. 
Cholesterol absorption is regulated by receptors on the apical membrane, 
Niemann-Pick C1-like 1 protein (NPC1L1) and ATP-binding cassette (ABC) 
transporters 5 and 8 (ABCG5/G8). In the enterocyte chylomicrons are formed 
and transferred to the liver via lymphatic system. 
About half of the cholesterol in the body derives from endogenous (de novo) 
synthesis, which occurs mainly in the liver and the intestine.  
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Synthesis of cholesterol begins from the acetyl-CoA, and it is composed of 
the following major steps: 1. Acetyl-CoAs are converted to 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA); 2. HMG-CoA is converted to mevalonate; 
3.Mevalonate is converted to isopentenyl pyrophosphate (IPP); 4. IPP is 
converted to squalene; 5. Squalene undergoes a two-step cyclization to yield 
lanosterol; 6. Two alternative pathways leading to cholesterol formation can 
be activated.  
Rate limiting step occurs at the HMG-CoA reductase followed by mevalonate 
formation. 
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Figure 1: Simplified diagram of cholesterol and oxysterols metabolism (From Leoni et 
al, 2013). Liver cholesterol 7a-hydroxylase (CYP7A1) converts cholesterol into 7a –
hydroxycholesterol (7aOHC), the main precursor of the neutral bile acid pathway. 
Cholesterol 27-hydroxylase (27OHC) expressed in different cell types converts 
cholesterol into 27-hydroxycholesterol (27OHC), precursor of the acidic bile acid 
pathway. Neuronal specific cholesterol 24-hydroxylase (CYP46A1) is responsible for 
24S-hydroxycholesterol (24OHC) formation. Cholesterol autoxidation in presence of 
lipid peroxidation and reactive oxygen species (ROS) results into formation of several 
oxysterols 26. 
 
The two possible pathways activated to obtain cholesterol are: via lathosterol 
(Kandutsch-Russell pathway) or via desmosterol (Bloch pathway), as 
summarized in the figure below. 
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Figure 2: Overview of cholesterol metabolism. 
 
Cholesterol is transported in the serum within Low Dense Lipoproteins 
(LDLs).  
The liver synthesizes and secretes VLDLs (Very Low Density Lipoprotein) 
which are rich in triglycerides and apolipoproteins. Their degradation, 
through loss of triglycerides and apolipoproteins gives origin to Intermediate 
Density Lipoproteins and LDL, through the action of endothelial cell-
associated lipoprotein lipase.  
In peripheral tissues, the cellular upload of LDL is mediated by the LDL 
receptor (LDLR). The transcription of LDLR is regulated by SREBPs 
transcriptional factors and is downregulated when cellular concentration of 
cholesterol increases, so that LDL remains in the blood. 
The removal of excess peripheral cholesterol to the liver involves a complex 
pathways and it is referred as “Reverse cholesterol transport”.  
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Cellular cholesterol efflux, in peripheral tissues, is mediated by HDLs. It can 
then be transferred to VLDLs and LDLs via the action of cholesteryl ester 
transfer protein (CETP) which is associated with HDLs.  
Ultimately, cholesterol is excreted in the bile as free cholesterol or as bile 
salts following conversion to bile acids in the liver. 
The catabolism of cholesterol into bile acids occurs by two major pathways: 
the classical and the alternative (acidic pathway). In the classical pathway 
7-hydroxycholesterol is formed, while in the alternative pathway, the first 
step involves the oxidation of cholesterol to 27-hydroxycholesterol. 
 
1.2.3.2 Phytosterols and diet 
Phytosterols cannot be synthesized by humans and are always derived from 
the diet. Phystosterols (or plant sterols) occur naturally in vegetable oils and 
in smaller amounts in vegetables. They have been used as marker of 
cholesterol absorption, since cholesterol absorption is highly variable, and 
influenced by several factors (e.g. diet, genetics etc.). 
The most abundant plant sterols are sitosterol and campesterol and several 
studies suggest that a high intake of phytosterols is associated with lower 
plasma cholesterol levels, in particular with lower total cholesterol and LDL. 
Their mechanism of action is related to competition with cholesterol (i.e. 
introduced with the diet from foods of animal origin) for intestinal absorption.  
Sarkinnen et al in 1997 reported a change of phystosterol levels in relation 
to the addition of vegetable oils in the diet in hypercholesterolemic subjects 
27. Another study reported that vegans have significantly higher 
campesterol (both absolute value and ratio over total cholesterol) and 
sitosterol (only absolute value) compared to omnivores 28. 
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On the contrary, a recent study showed no associations between absolute 
plasma campesterol and sitosterol with dietary patterns 29.The authors 
suggest as possible explanation of this finding the fact that in humans less 
than 5% of ingested plant sterols are absorbed and that the absorption of 
plant sterols is much less and their excretion into bile is much faster than 
cholesterol. 
Based on the results of recent meta-analysis that associated phytosterols 
administration with decreased LDL plasma levels 30 several Scientific 
Societies suggest to administer 2g/day of phytosterols to 
hypercholesterolemic patients 31-32. 
However the cholesterol lowering effect of functional foods and specific diets 
rich in plat sterols is still matter of debate. 
1.2.3.3 De novo cholesterol synthesis and diet 
Endogenous synthesis of cholesterol is controlled by several factors 
including: genetics, age and metabolic state. For example individuals with 
higher BMI show an increased cholesterol synthesis which is accompanied 
by a decreased intestinal absorption 33. 
Lanosterol is an intermediate of cholesterol synthesis that derives from 
squalene and that can be processed into lathosterol or desmosterol. Studies 
analysing lipids metabolism have been using its serum concentration 
corrected for total cholesterol concentration as biomarker of cholesterol 
endogenous synthesis. It exert a regulating role in the de novo sinthesys. In 
facts when intracellular levels of lanosterol are high, throuhg INSIG1 protein, 
it promotes the degradation of HMG-CoA reductase, the rate limiting enzyme 
in cholesterol synthesis. 
Lathosterol is produced from lanosterol in the Kandutsch-Russell pathway 
as intermediate of cholesterol synthesis. Its serum concentration corrected 
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for cholesterol concentration is the most commonly reported marker of 
cholesterol de no novo synthesis, and recently it was validated in a 
methodological study aimed at studying the correlations between non-
cholesterol sterols and gold standard functional techniques 28. 
Several evidences suggest a role of plant-based diets in decreasing serum 
levels of lathosterol. A study conducted in patients with Rheumatoid Arthritis 
showed that a vegan diet determined a decrease in serum cholesterol and 
lathosterol concentrations 34. This observation was confirmed in a trial 
comparing surrogate markers of cholesterol metabolism, reporting a 
significant difference of 272 mg/d between vegans and omnivores 28. 
Another study reports that lathosterol to cholesterol ratio significantly 
decreased in response to very-high-fructose diet, in health subjects 35. 
Individuals with Metabolic Syndrome or Diabetes show higher desmosterol 
and lathosterol concentrations accompanied by lower concentrations of 
cholesterol absorption markers 36. 
Desmosterol is produced from lanosterol in the Bloch pathway as 
intermediate of cholesterol synthesis. Studies analysing lipids metabolism 
have been using its serum concentration corrected for total cholesterol 
concentration as biomarker of cholesterol synthesis. Desmosterol levels has 
been associated to gender, being higher in women than man 36. 
Desmosterol is also a regulator of cholesterol metabolism that was 
associated to activation of cholesterol efflux and downregulation of de novo 
cholesterol synthesis 37. 
A small dietary trial, showed that, compared to placebo, a diet 
supplementation with plant sterols increased serum levels of plant sterols 
such as campesterol and sitosterol and increased markers of cholesterol 
synthesis such as desmosterol and lathosterol, without changing cholesterol 
serum levels 38. 
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1.2.3.4 Cholesterol turnover and diet 
Cholesterol can be removed from the body by two mechanisms: it can be 
removed directly as free cholesterol or after conversion to bile acids for faecal 
excretion. Bile acids synthesis is the main pathway of cholesterol excretion. 
“HDL-mediated reverse cholesterol transport is the most important 
mechanism regulating cholesterol homeostasis, allowing a flux of cholesterol 
from extrahepatic tissues to the liver. 
Oxidative mechanisms involving formation of side-chain oxidized oxysterols 
can be regarded as alternatives to this mechanism” 39, as summarized in 
the figure below. 
 
Figure 3: Elimination of cholesterol from macrophages by the sterol 27-hydroxylase 
mechanism an alternative to the HDL-dependent reverse cholesterol transport (From 
Bjorkhen 2012)39 
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Cholesterol from peripheral tissues is converted to 27-hydroxycholesterol 
(27-OHC), by sterol 27-hydroxylase (CYP27A1) which is widespread, but 
particularly represented in the vascular endothelium and macrophages. The 
severity of cerebrotendinous xanthomatosis, due to CYP27A1 deficiency, 
indicates the critical role of 27-OHC in cholesterol homeostasis.  
27-OHC is then transported from the tissues to the liver, where it is converted 
to bile acids (via acidic pathway), contributing to cholesterol efflux 
independently from HDL 40.  
A study on healthy males showed that subjects with low HDL plasma levels 
have increased 27-OHC over cholesterol ration and supports the role of 
oxysterols as alternative mechanism of cholesterol excretion. “This pathway 
could be a compensatory mechanism for the ineffective reverse cholesterol 
transport of individuals with very low levels of HDL-C” 41.  
 
24S-hydroxycholesterol (24-OHC) is mainly produced by cholesterol 
degradation in the brain and it reflects the brain turnover. The enzyme 
converting cholesterol in 24-OHC (24S-hydroxylase, known as CYP46) is 
located exclusively in neuronal cells and levels of 24-OHC in cerebrospinal 
fluid (but not in blood) have been associated with neurological disease (e.g. 
cognitive impairment, Alzheimer Disease etc.) 42. CYP46 was found to be 
highly resistant to most regulatory axes. Oxidative stress was one of the very 
few factors affecting the expression of the enzyme 43. 
 
25-hydroxycholesterol (25-OHC) is a powerful inhibitor of HMG-CoA 
reductase, the rate-limiting enzyme in sterol biosynthesis. It is present in all 
tissues but its physiological function is still uncertain 44. There is some 
evidence that ABC transporters may be involved in the transport of 25-OHC, 
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suggesting an alternate mechanism of cholesterol efflux, similar to HDL-
independent 27-OHC efflux.  
 
Limited information is available on the plasma concentration of oxysterols in 
relation to diet. Some authors reported a strong correlation between 
oxysterols consumed with food (e.g. mainly from western diets/fast food type) 
and their level in plasma 45. A small trial using different fat-enriched meats 
showed a decrease of plasm 24-OHC and 27-OHC after the dietary 
interventions. These modifications were observed after only 10 days of 
dietary intervention, even if no changes in LDL and total cholesterol were 
observed 46. 
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1.2.4 State of the art on nutrigenomics and lipid levels 
The physiological effect of a nutrient is determined by multiple biochemical 
processes occurring at molecular level during: gastro-intestinal digestion and 
absorption, hematic transport, cellular uptake and metabolism, and finally 
excretion. Each process is controlled by multiple genes, their polymorphisms 
and their interactions. All can potentially modify the host’s physiological 
response to diet 47. 
Several studies indicate that the genetic background is associated to 
differences in the ability of digesting a number of nutrients. The variants that 
create this predisposing genetic background may be the result of 
evolutionary events, since ethnic groups adapted over the centuries to exploit 
optimally the foods available locally. In has been repeatedly demonstrated 
that genetic variants associated to the synthesis of enzymes involved in 
nutrients metabolism are more or less represented in a population in relation 
to the regional food history (e.g. “lactase persistence” in adults and regional 
dairy farming history) 48. 
In the past decades, nutrigenomics has emerged as a new discipline, 
recognizing that the effects of nutrition on health and disease cannot be 
understood without a profound knowledge of how nutrients act at the 
molecular level 49. 
The concept behind nutrigenomic studies, is that unbalanced diets “may shift 
the balance between healthy and diseased conditions, increasing the risk of 
metabolic and immune disturbances, particularly in genetic predisposed 
subjects”, as summarized in the figure below 50. 
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Figure 4: Overview of the concept behind nutrigenomic: dietary exposures may have 
different effects in relation to the genetic background and may determine the shift 
between homeostasis and metabolic/immune disturbances only in susceptible 
individuals (from Curti et al, 2011) 50. 
 
It has been reported by several studies that extrinsic factors, such as 
pharmaceutical intervention and diet, exert different effects on cholesterol 
levels depending on the genetic background of the individual and on other 
factors (e.g. microbiome). For example Herron et al, suggested that men can 
be categorized in “hypo-responder, where plasma total cholesterol increases 
<0.05 mmol/L, or as hyper-responders, where there is an increase of ≥0.06 
mmol/L per each additional 100 mg dietary cholesterol, respectively” 51. 
At the same time, data from observational and intervention studies 
highlighted that genetic heterogeneity was partially responsible of the 
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marked inter-individual variability in the response of cholesterol metabolism 
to similar diets 52-53. 
A better understanding of the interactions between genetic background and 
diet has the potential to support tailored programmes for 
hypercholesterolemia prevention/management via modification of dietary 
recommendations 54. 
The literature related to nutrigenomic of cholesterol (i.e. total cholesterol, 
LDL, HDL) is modest, a recent review indicates that 69 studies (mostly small 
size interventional trials) were available in 2015 53. In addition most of them 
concentrated on: the fat content of the diet, on dietary energy intake or/and 
on characteristics of the fatty acids introduced with the diet. As far as we 
know there are no nutrigenomic studies published so far, that consider 
vegetarian diet (vegetarian/no restriction) and just one study (recently 
published by our group) that consider anthocyanins/polyphenols dietary 
intake as interaction factor (i.e. environment) 55. 
On the contrary there are large GWAS 56-59 reporting in a consistent 
manner several genes associated with LDL and HDL levels, some of which 
with clear biological meaning. 
In addition a number of nutritional studies reported that diet can modulate the 
activation/concentration of enzymes/proteins encoded by the same genes 
reported in the GWAS. For example 1) paraoxanase 1 (PON1) activity and 
PON1 gene expression are modulated by anthocyanins-rich diets 60-61; 2) 
PCSK9 enzymatic activity has been reported to be modulated by several 
nutrients 62. 
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1.2.5 State of the art on tools for personalized nutrition for CVD 
prevention 
 
Mobile health, or mHealth, is defined as the use of mobile tools (e.g. phone, 
tablets etc.) to foster health promotion or disease management. 
New technological approaches (genomics, metabolomics, etc.) have 
boosted knowledge production in health, nutrition and genetic areas. 
However such knowledge is only partially available due to the extreme 
fragmentation of different sources, the lack of operative standards and the 
lack of correlation/integration between data from different domain (clinical, 
nutritional, lifestyle, genetic etc.). mHealth is opening up enormous 
opportunities for the delivery of self-managed, efficient and affordable health 
care at a time when the demands on health and social care services continue 
to increase. However, there is still a gap between concept and translation 
into real health care and lifestyle changes. 
Many mHealth interventions have focused on hypertension. A recent review 
63 reports that among the 11 trials evaluating the efficacy of different 
mHealth solutions to support blood pressure control, 7 reported a 
significantly improved outcome in the group using mHealth. However the 
interventions were very different in nature and duration. 
There are less mHealth apps targeting dyslipidemia control. The same 
review cited above reports 4 interventional trials using mHealth for the 
management of hypercholesterolemia, with inconsistent results. Also in this 
case the type of support provided through mHealth was very different and 
ranged from reminders to enhance adherence to lipid-lowering therapies to 
more comprehensive approaches, promoting also lifestyle changes. 
The largest trial published so far (TEXTME) was conducted in Australia on 
more than 700 patients with coronary heart disease, and showed that the 
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intervention group achieved significantly lower LDL levels, compared to the 
control group, along with reductions in blood pressure and BMI and 
significant positive changes in lifestyle (i.e. increase in physical activity, and 
a reduction in smoking) 64. 
In addition there is an increasing number of health Apps on the market, with 
more than 165,000 mHealth apps available in the Apple iTunes and Android 
app stores, but it is hard to find scientific validated 
applications/software/platform able to provide valid suggestions, keeping 
under consideration different correlation approaches. Furthermore there is 
lack of evidence for the efficacy and safety for most apps. Possible 
certification schemas have been proposed, but currently there is no accepted 
standard. 
Finally, despite the good technical quality of several Apps on the market, 
their use do not foresee a communication between the patients and the care 
team, and data collected through mHealth are not included in electronic 
health records (EHRs). Thus mHealth is often a stand-alone intervention, and 
this approach may limit its efficacy and its adoption in routine practice 65. 
As stated above, the role of nutrition in health promotion and chronic 
disease prevention is widely recognized, as well as the need of decision 
support tools for professionals, able to merge and take into account the large 
amount of data generated by researcher and updated international 
guidelines. Also there is the need to increase the awareness towards healthy 
behaviors in the general society, to allow a life-course approach in CVD 
prevention. 
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2 AIMS AND OBJECTIVES 
The aim of this thesis is to explore the effects of dietary components, 
particularly anthocyanins and polyphenols, on CVD risk factors and of 
possible molecular mechanisms underlying the large individual variability in 
the response to diet-induced changes in cholesterol levels. This kind of 
evidences are needed to develop personalized prevention tools. This aim 
has been addressed through the following specific objectives: 
Objective 1: Evaluation of the association between well-established risk 
factors of CVD (i.e. total cholesterol, LDL, HDL, triglycerides, blood pressure 
etc.) and markers of atherosclerosis (i.e. Intima Media Thickness) Vs dietary 
micronutrients/dietary patterns in apparently healthy subjects. 
Objective 2: Evaluation of possible mechanism of action of dietary 
micronutrients/diet on lipid levels, by studying non-cholesterol sterols which 
are implicated in cholesterol homeostasis. 
Objective 3: Evaluation of the possible mechanism of action of dietary 
micronutrients/diet on influencing lipid levels, considering also the genetic 
background, by studying Gene*Environment (G*E) interactions. Due to the 
low number of genes reported in G*E interactions, considering as 
environment the dietary patterns (i.e. vegetarian diet, adherence to 
Mediterranean diet) and micronutrients under study, we adopted an 
exploratory approach. At this purpose we concentrated on four candidate 
genes (CYP7A1, INSIG2, LPA, PCSK9) for nutrigenetic analysis on “overall 
diet” and on one candidate gene (PON1) for nutrigenetic analysis on 
polyphenols/anthocyanins. 
Objective 4: Development of tools for personalized nutrition, combining the 
use of nutritional evaluations and genetic risk scores with established risk 
scores for atherosclerosis and CVD.  
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3 MATERIALS AND METHODS 
3.1 Recruitment and data collection  
In the context of the project ATHENA a multicentre cross sectional study was 
conducted in Milano. The recruitment started in June 2012 and was 
completed in December 2013. The dietary follow up was completed in March 
2015. 
Healthy volunteers were contacted through publication of an invitation letter 
in the Hospital websites and among those visiting the units for routine 
controls. Patients were considered eligible if meeting all the following 
inclusion and exclusion criteria. 
Inclusion criteria: 
 Age between 18 and 70 years; 
 Able to read and understand the study information sheet and to sign 
the informed consent form; 
 Absence of known cardiac diseases.  
Exclusion criteria: 
 Patients with malignancies or severe psychiatric diseases; 
 Patients with severe cardiac disease such as myocardial infraction or 
cardiac failure; 
 Patients with chronic kidney disease higher than stage 3; 
 First degree relatives of an already enrolled subject;  
 Patients that did not sign the informed consent form. 
 
According to the study protocol, the phenotypic data collection included: 1) 
laboratory testing for a wide variety of parameters (among which plasma lipid 
profile); 2) anthropometric measurements (weight, height and waist 
circumference); 3) blood pressure assessment; 4) renal echography (with 
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resistance index assessment); 5) echocardiographic examination; 6) carotid 
doppler. 
3.2 Dietary characterization 
Dietary habits were collected by trained nutritionists through 24 hours recall 
interviews, which were repeated 4 times, seasonally. The main tools used in 
dietary interviews were: 
Food Atlas (edited by Scotti-Bassani) including 99 tables with the visual 
representation of portions/quantities of foods/beverages commonly 
consumed in Italy, as a support for the volunteer and the nutritionist in 
understanding the amount (grams) of foods. 
 
Figure 5: Tables from the food atlas, to facilitate the collection of information related 
to food portion (From Scotti-Bassani Atlas). 
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Food Composition Table: the “Food Composition Database for 
Epidemiological Studies in Italy” (IEO) was adopted, with the following 
additions:  
 Anthocyanins contents of several foods from the USDA “Database for the 
Flavonoid Content of Selected Foods” and from the analysis conducted 
in ATHENA; 
 Foods and food items used by vegans/vegetarians (calculated by 
professional nutritionists, based on ingredients and recipes); 
 Total Polyphenol contents from the “Phenol Explorer 2.0” Database. 
 
Dietary information collected during the interviews were combined with 
macro and micronutrients data from the Food Composition Table in order to 
compute the individual daily intake of macro and micronutrients. 
In addition, during fall 2014, a subset of the volunteers was also asked to 
participate to another nutritional assessment (promoted at IEO - Istituto 
Europeo di Oncologia, Milano, Italy) aimed at validating a questionnaire to 
evaluate adherence to Mediterranean diet. The questionnaire included 15 
items related to the frequency of specific foods consumption. For each 
question the interviewed had to choose one among 5 possible predetermined 
answers. 
3.3 Laboratory analysis 
Blood sample in fasting state were collected during the visit.  
The determination of HDL, LDL, total cholesterol and triglycerides was 
carried out by means of automatic clinical chemistry instrumentation (Abbott 
Architect 8000). Samples were analyzed in batches after storage at −40 °C 
for a time not exceeding one month. 
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For all subjects with sufficient plasma quotes (N=312), non-cholesterol 
sterols were analysed. To a screw-capped vial sealed with a Teflon septum, 
0.25 mL of plasma were added together with 1000 ng of D7-lathosterol, 100 
ng of D6-desmosterol, 100 ng of D6-lanosterol, 2500 ng of D7-campesterol 
and 2500 ng D7-β-sitosterol, 50 ng of D6-24-hydroxycholesterol, 50 ng of 25-
hydroxycholestero and and 100 ng D6-27-hydroxycholesterol l as internal 
standards, 50 μl of butylated hydroxytoluene (5g/l) and 50 μl of K3-EDTA (10 
g/l) to prevent auto-oxidation.  
Alkaline hydrolysis was allowed to proceed at 40°C for 30 minutes in the 
presence of ethanolic 1 M potassium hydroxide solution. After hydrolysis, the 
sterols were extracted twice with 5 ml cyclohexane. The organic solvents 
were evaporated under a gentle stream of argon and converted into 
trimethylsilyl ethers with BSTFA. 
Gas chromatography mass spectrometry (GC-MS) analysis was performed 
on a GC equipped with an Elite column (30 m×0.32 mmid×0.25 mm film 
;Perkin Elmer, USA) and injection was performed in splitless mode and using 
helium (1 ml/min) as a carrier gas. The temperature program was as follows: 
initial temperature of 180 °C was held for 1 min, followed by a linear ramp of 
20°C/min to 270 °C, and then a linear ramp of 5°C/min to 290 °C, which was 
held for 10 min. 
The mass spectrometer operates in the selected ion-monitoring mode. Peak 
integration is performed manually, and sterols are quantified from selected-
ion monitoring analysis against internal standards using standard curves for 
the listed sterols. Additional qualifier (characteristic fragment ions) ions were 
used for structural identification. Interassay CV was 2.3% for lathosterol, 3.1 
% for lanosterol, 4.2 % for campesterol, 3.9 % for β-sitosterols, 3.3 % for 24-
S-hydroxycholesterol, 4.6% for of 25-hydroxycholesterol and 3.6 % for 27-
hydroxycholesterol. Recovery ranged from 98 up to 103%. 
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3.4 Genotyping  
DNAs were extracted from blood samples periodically shipped from the 
Recruitment Centres and underwent quality controls, through 1% agarose 
gel electrophoresis before genotyping. 
Samples were genotyped on an Illumina iScan platform, using the Illumina 
HumanCore array. The HumanCore array contains 200K highly informative 
genome-wide tag-SNPs including indels and updated exome focused 
markers. The HumanCore allows a genome-wide approach, as 200K SNPs 
are directly genotyped, while recovery of a higher number of genotype data 
is performed through imputation. 
Raw intensity data were analysed with the Illumina Software Genome Studio 
for genotype calling, using the Illumina reference cluster file. 
The genotyped sample included 495 individuals who underwent quality 
controls in accordance with the protocol written by C.A Anderson et al. 66. 
DNA call rate threshold was set at 0.95. 1 DNA with call rate < 0.95 was 
excluded from the final data set.  
No subjects with sex mismatch (difference between gender reported in 
demographic data and gender estimated with SNPs mapping in sex 
chromosomes) were identified.  
We removed 8 subjects for heterozigosity rate and using genome-wide 
Identity by Descent (IBD) estimation in PLINK, we removed 15 related 
subjects. Using Golden Helix software we performed the principal component 
analysis and we removed 4 outliers (i.e. individuals that exceed a default 
number of standard deviations from the whole sample). The final sample 
included 465 subjects (185 males, 280 females), table 1. 
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Total Genotyped 495 
Call Rate < 95%  1 
No phenotype 1 
Related 15 
Sex Mismatch 0 
Heterozigosity Rate 8 
PCA 4 
GOOD QC SAMPLES 465 
 
Table 1: Summary of the quality controls conducted after genotyping. 
 
We used imputation to increase the number of SNPs available for the 
association analysis. Imputation is a method to predict genotypes at non-
directly genotyped SNPs.  
In the present study, genome-wide imputation was performed, starting from 
SNPs experimentally genotyped in our dataset, with >99% call rate and minor 
allele frequency >1%, in two steps:  
1. we used SHAPEIT 67 software to estimate the haplotypes from 
genotype data,  
2. we used MINIMAC software 68 to impute data using as reference 
the HapMap CEU haplotypes (release 22).  
Imputation accuracy was estimated using the R-squared (Rsq), also called 
coefficient of determination, that measures how well the imputed data fits a 
statistical model (i.e. the linear regression). 
Imputed SNPs with low imputation quality (Rsq<0.8 or MAF<1%) were 
excluded from the dataset (Table 2). 
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The results of imputing activities are summarized in Table 2. 
 
N % 
tot SNPs 2543887 100.00 
Rsq>= 30% 2418882 95.09 
Rsq>= 30% maf > 0.01 2383468 93.69 
Rsq< 30% 125027 4.91 
Rsq < 30% maf > 0.01 89567 3.52 
Rsq >= 80% 2002145 78.70 
Rsq >= 80% maf > 0.01 1991990 78.30 
 
Table 2:  results of imputing activities 
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3.5 Statistical Analysis 
The following paragraphs describe the statistical analysis conducted to 
answer to the first three objectives of the thesis. 
Objective 1: Evaluation of the association between well-established 
risk factors of CVD and dietary factors 
The study sample was characterized through descriptive analysis (mean, 
standard deviations and distributions). For each subject with at least two 
dietary recalls, the daily intake of macro and micronutrients was computed. 
To assess the differences in phenotypic and demographic data between 
males and females we used Ttest for quantitative data and Chi-squared test 
for qualitative data. As nutrients did not show normal distributions we used 
Wilkoxon rank sum test to assess the differences in macro and 
micronutrients between omnivores and vegetarians. For dietary data with 
marked non normal distributions (i.e. anthocyanins, polyphenols and 
Mediterranean diet score), we divided the data in tertiles. 
To explore the association between CVD risk factors (i.e. Total cholesterol, 
LDL, HDL, Atherogenic Index of Plasma – AIP-, LDL/HDL ratio, BMI, waist 
circumference, systolic and diastolic blood pressure and mean IMT, 
calculated as a mean between left and right IMT) and diet, we used multiple 
linear regression models adjusting for the main confounders shown to 
influence the phenotype (i.e. age, sex, BMI, smoking and self-reported sport 
intensity), using STATA 14.  
Objective 2: Evaluation of possible mechanism of action of dietary 
micronutrients/diet on lipid levels, by studying sterols implicated in 
cholesterol homeostasis 
33 
 
We characterized through descriptive analysis (mean, standard deviations 
and distributions) non cholesterol sterols associated to 1) cholesterol 
absorption (i.e. sitosterol and campesterol); 2) cholesterol de novo synthesis 
(i.e. lathosterol, desmosterol and lanosterol) and 3) cholesterol turnover (i.e. 
27-OHC, 24-OHC, 25-OHC). 
We conducted analysis to explore the association between non-cholesterol 
sterols and specific nutrient/dietary patterns, considering absolute values 
and their ratios over total cholesterol (which is the most commonly reported 
data in published studies), using multiple linear regression models in which 
the main confounders shown to influence sterols levels were used as 
covariates (i.e. age, sex, BMI), using STATA 14. Data of anthocyanins, 
polyphenols and Mediterranean diet score were divided in tertiles. 
We explored the correlation between non cholesterol sterols and serum 
cholesterol (i.e. total cholesterol, LDL, HDL) using Spearman correlation. 
We computed the ratios between different non-cholesterol sterols and we 
analyzed their differences among vegetarians and omnivores using Ttest. 
Objective 3: Evaluation of the possible mechanism through which 
dietary micronutrients/diet can influence lipid levels, by studying G*E 
interactions 
We analysed the presence of interactions between selected genes and the 
following “Environments”: 
1. “No-restriction” or “Vegetarian” diet 
2. “Low anthocyanin intake” corresponding to the lower tertile and “High 
anthocyanin intake” corresponding to the higher tertile 
3. “Low polyphenols intake” corresponding to the lower tertile and “High 
polyphenols intake” corresponding to the higher tertile. 
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To explore the G*E interactions with “overall” diet we tested 4 genes, 
encoding proteins previously shown to be modulated by diet, and in which 
map candidate SNPs for LDL, identified in large GWAS 56-58. Genes 
CYP7A1, INSIG2, PCSK9 and LPA were assessed. We performed a 
quantitative trait interaction analysis (G*E analysis) testing each SNP 
associations with LDL in “vegetarian” and “no restriction” diet as 
environments. 
To explore the G*E interactions with anthocyanins and polyphenols, as no 
previous nutrigenetic studies were available, we selected PON1 gene, which 
was associated to HDL in large GWA 59 and which encodes an enzyme 
strongly modulated by anthocyanins. 
We performed a G*E analysis to test the association of the SNPs in PON1 
with Total cholesterol, HDL, LDL, Triglycerides and AIP in low and high 
anthocyanins and polyphenols intake environments.  
 
For all genes we explored the entire gene, including all the SNPs within the 
gene boundaries and extending the analysis 15 Kb upstream and 
downstream the 5’ and the 3’ of each gene. We used this last option in order 
to investigate possible regulatory regions. 
All phenotypes were analysed as residuals, adjusted for sex, age, BMI and 
the first 10 principal components calculated using R software. For each trait, 
individuals with missing data were excluded from the analysis. To correct for 
multiple testing for each gene we defined a Bonferroni threshold.  
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3.6 Development of tools for personalized nutrition in CVD 
prevention 
 
In the context of ATHENA, together with KOS Genetic and Politecnico di 
Milano, an integrated platform, called Dietary Monitoring Solution (DMS), 
was developed to collect phenotypic, genetic and lifestyle information. The 
DMS includes a Case Report Form (CRF) and a linked mHealth application. 
The CRF, aimed at collecting information related to cardiovascular diseases 
and dietary risk factors was designed with the collaboration of domain expert 
clinicians and nutritionists. A specific software processed nutritional data 
collected during dietary interviews and computed macro and micronutrients 
intake from each food/meal. The mHealth application was designed to track 
subject dietary and lifestyle habit in his/her ecological context. 
Genetic information, represented by Single Nucleotide Polymorphisms 
(SNPs) was organized in PED and MAP files, which constitute standard 
formats for the most widely used genomic analysis software.  
The system can be integrated with a semi-automatic Decision Support 
System (DSS), which is built on a set of rules that uses as input: 
 SCORE risk, is used for risk calculation: the formula is based on few 
parameters: systolic blood pressure, total cholesterol, high density 
cholesterol and smoking status. Such endpoints are not the best 
available predictors of atherosclerosis, but have relevant advantages 
that make them well suited to be used in a risk score meant for 
“apparently healthy” subjects: inexpensive, uninvasive, easy to 
measure, well correlated with atherosclerosis. 
 Normality ranges: 
o Available from international guidelines for BMI; 
o Provided by the laboratory for biochemical parameters; 
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 Food preferences: from the available daily recalls included in the 
individual records. 
 Nutritional Guidelines: from LARN “Reference Levels for the intake of 
nutrients and energy in the Italian population” tables. 
 For LDL and HDL we developed algorithms that propose: 
o optimal cholesterol levels in relation to the presence of 
concomitant risk factors,  
o dietary or lifestyle interventions 
according with the “American Association of Clinical Endocrinologists’ 
guidelines for management of dyslipidaemia and prevention of 
atherosclerosis” 69. 
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4 RESULTS 
 
The study sample included 465 apparently healthy individuals, divided in 
vegetarians and omnivores (Table 3). Only 450 individuals, those with at 
least two dietary interviews, were considered for analysis on dietary aspects 
and for nutrigenomic. 15 individuals were lost during the follow up (i.e. only 
one dietary assessment). 
 
Table 3: Number of volunteers recruited in the observational study, number of eligible 
after dropping subjects not meeting inclusion/exclusion criteria, number of eligible for 
genetic analysis and those considered for analysis on dietary aspects (having at least 
2 dietary assessments). 
Study sample 
 Recruited Eligible Genetics > 1 dietary recall 
OMNIVORS 381 374 346 331 
VEGETARIANS 122 120 119 119 
TOTAL 503 495 465 450 
 
Demographic characteristics of the subjects studied are summarized in Table 
4. 
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Table 4: Demographic and metabolic parameters of the study sample (mean±SD). Abbreviations (BMI=Body Mass Index; WC= Waist 
Circumference; TGL=triglycerides; LDL=low density lipoprotein; HDL=high density lipoprotein; IMT=Intima Media Thickness) 
Phenotypes Females Males 
P-value 
TOTAL 
Sex 270 180 450 
Age 49.78 ± 13.13 53.19  ±14.9 0.011 51.14 ±13.96 
BMI  24.14 ± 5.13 25.51 ±4.25 0.002 24.68 ±4.84 
WC 83.17 ± 12.77 94  ±11.88 - 86.70 ±13.35 
Low physical activity 35.51% 27.61% NS 32.35% 
Smoke (yes) 17.36% 16.57% NS 17.05% 
Vegetarian 31.23% 19.34% 0.005 26.44% 
TGL (mg/dl) 97.02 ± 57.26 120.53 ± 69.25 <0.001 106.32 ± 60.51 
HDL (mg/dl) 58.90 ± 12.25 48.55 ± 12.36 <0.001 54.63 ± 13.27 
LDL (mg/dl) 128.03 ± 34.72 120.88 ± 33.85 0.036 125.18 ± 34.51 
CHOL (mg/dl) 206.57 ± 40.08 193.63 ± 36.89 <0.001  201.42 ± 39.28 
LDL/HDL 2.27 ± 0.81 2.61 ± 0.84 <0.001 2.40 ± 0.84 
SBP 120.43 ± 19.37 128.21 ± 18.15 <0.001 123.57 ± 19.24 
DBP 74.17 ± 10.89 78.44 ± 10.77 <0.001 75.89 ± 11.03 
IMT (mean) 0.58 ± 0.1 0.62 ± 0.12 - 0.59 ± 0.11 
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Females were more represented than males, being 59.78% of the sample. 
Female were also more represented in the vegetarian group (70.6%) 
compared to the omnivores group (see Table 5). 
The mean age of our sample was 51 years (±13.96). The average BMI, SBP, 
DBP, IMT, TGL, LDL and HDL are within normal ranges. Total cholesterol is 
slightly above of the reference threshold of 200 mg/dl.  
Females are slightly younger than males and have slightly lower BMI. 
Females have higher levels of cholesterols compared to males, but a better 
LDL/HDL ratio. On the contrary males have higher TG and more elevated 
systolic and diastolic blood pressure. 
Differences between males and females in waist circumference and IMT 
were not evaluated as they are expected in relation to different average body 
size.   
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Objective 1: Evaluation of the association between well-established 
risk factors of CVD Vs dietary micronutrients/dietary patterns 
Table 5 shows the average daily intake of selected nutrients and the 
adherence to Mediterranean diet, in the total sample and in the groups of 
omnivores and vegetarians.  
Table 5: Average daily intake of selected nutrients and adherence to Mediterranean diet 
(TP=Total Proteins; AP=Animal Proteins; LT=Lipids Total; SFA=Saturated Fatty Acids; 
PUFA=Polyunsaturated Fatty Acids; CA= Carbohydrates; ATC=Anthocyanins; 
PL=Polyphenols; MD=Mediterranean diet). Results from Wilkoxon rank test are 
indicated: ** P<0.001; *P <0.05  
Nutrient Omnivores Vegeterians TOTAL 
Diet type 331 (73.6%) 119 (26.4%) 
450 
Females 186 (56.2%) 84 (70.6%) 
TP** 62.14 ± 17.72 48.17 ± 15.91 58.45 ± 18.31 
AP** 38.00 ± 15.26 5.81 ± 6.29 29.49 ± 19.58 
LT 59.40 ± 51.99 56.91 ± 22.46 58.74 ± 46.05 
SFA** 18.80 ± 8.25 12.88 ± 6.06 17.23 ± 8.15 
PUFA** 7.82 ± 3.75 9.91 ± 4.56 8.370 ± 4.09 
CA** 191.62 ± 57.03 212.49 ± 57.46 197.14 ± 57.82 
Starch 115.54 ± 42.81 108.74 ± 43.50 113.74 ± 43.05 
Fiber** 18.29 ± 9.31 31.22 ± 11.59 21.71 ± 11.47 
ATC* 22.80 ± 32.44 40.57 ± 69.41 27.50 ± 45.84 
PL** 1,016.59 ± 535.61 1,582.99  ± 897.79 1,166.37 ± 696.57 
MD  
(Higher 
tertile) 
21.31% 62.79% 32.12% 
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The two diets show marked differences for several nutrients: vegetarian diet 
is significantly higher in fiber, cholesterol, polyunsaturated fatty acids, 
polyphenols and anthocyanins. On the contrary the “no restriction diet” of the 
omnivores is higher in proteins, animal proteins and saturated fatty acids. 
As expected, a high adherence to Mediterranean diet is more frequent in 
vegetarians. 
Table 6 presents the results of multiple regression analysis evaluating the 
associations between markers of CVD and dietary factors. 
After adjusting for potential confounders, vegetarians show lower BMI 
compared to omnivores. This observation is significant also for individuals 
with high adherence to Mediterranean diet, compared to those with low 
adherence and for individuals reporting high intake of polyphenols compared 
to those reporting low intake of polyphenols. For such classes we observe 
also a lower waist circumference. Systolic and diastolic blood pressures 
show the same trend: they are significantly reduced in vegetarians (Vs 
omnivores), in subjects reporting higher adherence to Mediterranean diet 
(compared to those with low adherence) and in subjects reporting high intake 
of polyphenols (compared to those with low intake). 
As illustrated in Figure 6 and Table 6, vegetarian diet is associated with a 
strong reduction of LDL, total cholesterol levels and LDL/HDL ratio. 
Some individuals in both omnivores and vegetarians groups show LDL and 
total cholesterol levels higher than normal (200 mg/ml). 
Mediterranean diet was found significantly associated with an increase in 
HDL and with a better (lower) LDL/HDL ratio, but not with a decrease in LDL 
and total cholesterol. 
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Figure 6: Representation of LDL and total cholesterol serum levels in omnivores and 
vegetarians. 
None of the considered dietary factors influence IMT. 
High anthocyanins intake was not associated to any of the parameters 
considered.
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Table 6: Association between phenotypes related to CVD risk and diet/micronutrients (columns). Age, gender, sport intensity and 
smoke were always used as covariates, while BMI was considered for all phenotypes except for BMI itself. Sample (N=450), * 
Statistically significant 
Phenotype Mg Anthocyanins/day 
(tertiles ) 
Mg Polyphenols/day 
(tertiles) 
Diet (Omivorous Vs 
Vegetarian) 
Mediterranean Diet 
Score (tertiles) 
Coeff P Coeff P Coeff P Coeff P 
BMI -0.08 
(SE0.29) 
0.777 -0.98 
(SE 0.28) 
0.001* -2.64 
(SE 0.57) 
<0.001* -1.08 
(SE 0.32) 
0.001* 
Waist 
Circumference 
-0.322 
(SE 0.46) 
0.483 -1.01 
(SE 0.44) 
0.023* -1.14 
(SE 0.92) 
0.216 -1.93 
(SE 0.48) 
<0.001* 
SBP 0.46 
(SE 1.05) 
0.659 -2.34 
(SE 0.99) 
0.019* -5.13 
(SE 2.08) 
0.014* -3.06 
(SE 1.18) 
0.01* 
DBP -1.102 
(SE 0.59) 
0.064 -0.96 
(SE 0.61) 
0.119 -4.53 
(SE 1.26) 
<0.001* -1.56 
(SE 0.71) 
0.03* 
HDL 0.535 
(SE 0.68) 
0.435 0.57 
(SE 0.70) 
0.414 0.45 
(SE 1.4) 
0.758 1.63 
(SE 0.78) 
0.037* 
LDL 1.75 
(SE 2.01) 
0.383 0.27 
(SE 2) 
0.893 -18.24 
(SE 4.01) 
<0.001* -1.79 
(SE 2.22) 
0.423 
Total Cholesterol 1.51 
(SE 2.31) 
0.514 0.28 
(SE 2.26) 
0.90 -18.40 
(SE 4.61) 
<0.001* -0.70 
(SE 2.54) 
0.783 
LDL/HDL -0.014 
(SE 0.05) 
0.768 -0.035 
(SE 0.05) 
0.464 -0.4 
(SE 0.01) 
<0.001* -0.11 
(SE 0.05) 
0.039* 
AIP -0.021 
(SE 0.03). 
0.508 -0.032 
(SE 0.03) 
0.313 -0.038 
(SE 0.067) 
0.567 -0.05 
(SE 0.04) 
0.159 
Triglycerides -2.83 
(SE 3.37) 
0.402 -1.83 
(SE 3.47) 
0.598 -3.51 
(SE 7.21) 
0.627 -2.56 
(SE 4.14) 
0.537 
IMT_mean -0.0025 
(SE 0.006) 
0.651 -0.001 
(SE 0.01) 
0.794 -0.010 
(SE 0.014) 
0.406 -0.002 
(SE 0.01) 
0.723 
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Objective 2: Evaluation of possible mechanism of action of dietary 
micronutrients/diet on lipid levels, by studying sterols implicated in 
cholesterol homeostasis 
 
Table 7 and Table 8 describe mean and standard deviations (SD) of sterol 
levels measured in our sample, by dietary group and by tertile of 
anthocyanins/polyphenols daily intake. For each sterol is reported the 
absolute value. 
Table 7: Serum sterols in the different dietary groups (mean± SD). Absolute values in 
µg/L (N=312). 
Phenotype Diet  
(Omivores Vs Vegetarian) 
Mediterranean Diet 
Score (tertiles) 
Omnivore Vegetarian Lowest Highest 
Campesterol 
µg/L 
9,999.54 
±4624.66 
11,757.9 
±3929.48 
9,604.02 
±4321.15 
11,411.73   
±4378.11 
Sitosterol 
µg/L 
5,026.68 
± 2631.30 
6,398.51 
±2400.42 
4,628.57 
±2248.46 
6,335.29    
±2702.85 
Lathosterol 
µg/L 
2,742.16 
±1,294.75  
2,321.68 
±1,209.67 
2,972.75 
±1,284.99 
2,240.67 
±1,134.24 
Desmosterol 
µg/L 
98.92 
±35.24 
105.58 
±33.24 
99.83 
±33.06 
101.04 
±33.72 
Lanosterol 
µg/L 
147.20 
±72.56 
137.37 
±61.75 
157.18 
±74.687 
140.44 
±63.149 
24OHC 
µg/L 
51.18 
±15.15 
54.10 
±16.95 
51.03 
±14.13 
54.58 
±16.46 
25OHC 
µg/L 
23.39 
±12.449 
24.29   
±12.11 
24.07 
±13.76 
23.59 
±10.24 
27OHC 
µg/L 
147.23 
±49.16 
152.89 
±40 
149.54 
±43.81 
158.45 
±54.02 
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Table 8: Serum sterols in relation to anthocyanins and polyphenols daily intake 
(mean± SD). Absolute values in µg/L (N=312). 
Phenotype Mg Anthocyanins/day 
(tertiles ) 
Mg Polyphenols/day 
(tertiles) 
Lowest Highest Lowest Highest 
Campesterol 
µg/L 
10,077.88   
±4687.92 
10,634.21   
±4236.62 
9,993.71±
4822.86 
11,287.40 
±4341.74 
Sitosterol 
µg/L 
4,961.01 
±2438.18 
5,722.98   
±2559.58 
4,720.10  
±2376.39 
6,222.09   
±2693.20 
Lathosterol 
µg/L 
2,742.91 
±1,306.71 
2,619.20 
±1,145.12 
2,912.32 
±1,313.04 
2,473.33 
±1,115.16 
Desmosterol 
µg/L 
98.57 
±36.22 
104.95 
±33.73 
102.43 
±37.14 
106.09 
±30.37 
Lanosterol 
µg/L 
142.11 
±64.86 
151.14 
± 68.68 
148.42 
±74.49 
148.71 
±67.31 
24OHC 
µg/L 
51.25 
±14.76 
52.47 
±15.98 
52.10 
±15.32 
51.97 
±15.48 
25OHC 
µg/L 
22.31 
±0.64 
24.37    
±13.32 
22.43 
±11.15 
24.55 
± 14.93 
27OHC 
µg/L 
144.61 
±45.00 
158.28 
±50.20 
141.38 
±43.538 
158.39 
±51.40 
 
Table 9 and Figure 7 show that vegetarians have higher sitosterol 
concentrations (both absolute values and sitosterol/total cholesterol ratio) 
and higher campesterol concentrations (only campesterol/total cholesterol 
ratio) compared to omnivores.  
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Table 9: Results of association analysis between sterols and dietary factors, adjuster for age, gender and BMI. * Statistically significant 
Phenotype 
Mg Anthocyanins/day 
(tertiles ) 
Mg Polyphenols/day 
(tertiles) 
Diet (Omivorous Vs 
Vegetarian) 
Mediterranean Diet 
Score 
(tertiles) 
Coeff P Coeff P Coeff P Coeff P 
Absorption markers 
Campesterol 227.611 
(SE 314.99) 
0.470 501.427 
(SE 307.50) 
0.104 1,197.417 
(SE 622.33) 
0.055 665.33 
(SE 356.31) 
0.063 
Campesterol/chol 118.02 
(SE 147.82) 
0.425 279.51 
(SE 144.07) 
0.053 1176.487  
(SE 286.03) 
<0.001* 391.70 
(SE 164.43) 
0.018* 
Sitosterol 
 
303.32 
(SE 178.25) 
0.090 621.06 
(SE 171.80) 
<0.001* 1,105.529 
(SE 350) 
0.002* 680.245 
(SE 198.54) 
0.001* 
Sitosterol/chol 161.79 
(SE 86.23) 
0.062 328.91  
(SE 82.84)    
<0.001* 865.25 
(SE 164.94) 
<0.001* 367.80 
(SE 95.32) 
<0.001* 
Synthesis metabolites 
Lathosterol -18.79 
(SE 81.516) 
0.818 -130.36 
(SE 79.51) 
0.102  -49.45 
(SE 161.88) 
0.76 -213.867 
(SE 92.62)  
0.022* 
Lathosterol/chol 2.21 
(SE 37.48) 
  0.95 -61.66 
(SE 36.55)  
0.093 74.94 
(SE 74.32) 
0.314 -91.62 
(SE 42.67) 
0.033* 
Desmosterol 2.69 
(SE 2.43) 
0.269 1 
(SE 2.39) 
0.674 11.54 
(SE 4.79) 
0.017* 4.02 
(SE 2.68) 
0.134 
Desmosterol/chol 1.76 
(SE 1.13) 
  0.12 0.86 
(SE 1.11)     
0.77 10.71 
(SE 2.16) 
<0.001* 2.53    
(SE 1.2) 
0.038* 
Lanosterol 4.198 
(SE 4.78) 
0.381 2.48 
(SE 4.69) 
0.598 9.81 
(SE 9.49) 
0.302 -2.45 
(SE 5.35) 
0.648 
Lanosterol/chol 2.28 
(SE 2.13) 
0.287 1.60 
(SE 2.10) 
0.446 10.10 
(SE 4.21) 
0.017* -0.47 
(SE 2.40) 
  0.845 
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Phenotype 
Mg Anthocyanins/day 
(tertiles ) 
Mg Polyphenols/day 
(tertiles) 
Diet (Omivorous Vs 
Vegetarian) 
Mediterranean Diet 
Score 
(tertiles) 
Coeff P Coeff P Coeff P Coeff P 
Turnover markers 
24OHC 0.83 
(SE 1.12) 
0.460 0.33 
(SE 1.10) 
0.766 3.15 
(SE 2.23) 
0.158 1.24 
(SE 1.27) 
0.332 
24OHC/chol 0.418 
(SE 0.50) 
0.405 0.407 
(SE 0.49) 
0.407 3.67 
(SE 0.97) 
<0.001* 0.853 
(SE 0.567) 
0.134 
25OHC 0.98 
(SE 0.89) 
0.279 1.28    
(SE 0.87) 
0.144 1.61 
(SE 1.77) 
0.363 -0.73 
(SE 1.03) 
0.481 
25OHC/chol 0.544 
(SE 0.44) 
0.219 0.749 
(SE 0.432) 
0.084 1.85 
(SE 0.87) 
0.035* -0.255 
(SE 0.514)  
0.620 
27OHC 5.415 
(SE 3.19) 
0.091 6.43 
(SE 3.12) 
0.04* 13.06 
(SE 6.33)   
0.04* 9.50 
(SE 3.67) 
0.011* 
27OHC/chol 3.029 
(SE 1.41) 
0.032* 3.87 
(SE 1.37) 
0.005* 14.40 (SE 
2.69)  
<0.001* 5.443 
(SE 1.623) 
0.001* 
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Figure 7: Representation of sitosterol/total cholesterol ratio and campesterol/total 
cholesterol ratio in omnivores and vegetarians. 
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Subjects with high adherence to Mediterranean diet also show an increase 
in sitosterol concentrations (both absolute values and sitosterol/total 
cholesterol ratio) and in campesterol concentrations (only campesterol/total 
cholesterol ratio) compared to those with low adherence.  
A high consumption of polyphenols with the diet is also associated with 
increased sitosterol levels (both absolute value and sitosterol/total 
cholesterol ratio), but not with changes in campesterol levels. 
In subjects with high adherence to Mediterranean diet we observe a 
decrease of lathosterol concentration (both absolute value and 
lathosterol/total cholesterol ratio) and an increase of desmosterol 
concentration (only desmosterol/total cholesterol ratio). While in vegetarians 
we observe higher desmosterol concentrations (both absolute value and 
desmosterol/total cholesterol ratio). 
 
The ratio between sitosterol: campesterol is not significantly different in 
vegetarians compared to omnivores (ttest; P=0.49). The ratio between 
lathosterol: desmosterol (28.66± 13.16 in omnivores Vs 22.95±12.39 in 
vegetarians) is significantly different in favor of desmosterol in vegetarians 
(ttest; P<0.001) and in individuals with high adherence to Mediterranean diet 
compared to those with low adherence (31.48 ± 15.86 in the lower tertile Vs 
22.77± 11.57 in the higher tertile) (linear regression; P=0.003). 
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Table 10: Spearman correlations between sterol levels and cholesterol, for each 
correlation is reported the rho coefficient and the P-value (P). 
 LDL HDL Total Cholesterol 
 rho P rho P rho P 
Sitosterol 0.152 0.007 0.241 <0.0001 0.1456 0.01 
Campesterol 0.198 0.0004 0.1814 0.0013 0.1814 0.0013 
Lathosterol 0.389 <0.0001 -0.238 <0.0001 0.3781 <0.0001 
Desmosterol 0.356 <0.0001 -0.070 0.2154 0.3713 <0.0001 
Lanosterol 0.393 <0.0001 -0.177 0.0017 0.3734 <0.0001 
24-OHC 0.400 <0.0001 0.094 0.0987 0.4554 <0.0001 
25-OHC 0.299 <0.0001 0.045 0.4244 0.2879 <0.0001 
27-OHC 0.363 <0.0001 -0.138 0.0147 0.343 <0.0001 
 
Table 10 indicates that phytosterols (sitosterol and campesterol) are 
positively correlated with LDL, HDL and total cholesterol levels.  
Table 10 shows that intermediates of cholesterol de novo synthesis 
(lathosterol, desmosterol and lanosterol) are positively correlated with LDL 
and total cholesterol levels. Oxysterols (24-OHC, 25-OHC and 27-OHC) are 
positively correlated with LDL and total cholesterol levels. 27-OHC is 
negatively correlated with HDL. 
However if we stratify the analysis for dietary group we observe that the 
negative association observed between 27-OHC and HDL is not replicated 
in the vegetarian group (omnivores rho= -0.16, P= 0.0113 Vs vegetarians 
rho= -0.05; P=0.6).  
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Table 11, shows that if we stratify the analysis for vegetarians/omnivores, 
phytosterols show different degrees of correlation with cholesterol levels: the 
positive correlations between LDL and HDL and phytosterols observed in 
omnivores are not significant in vegetarians. This suggests that the overall 
type of diet may be a modifier of the correlation between phytosterols and 
cholesterol. 
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Table 11: Spearman correlation between phytosterols (SI=Sitosterol; CA=Campesterol) and cholesterol. , for each correlation is 
reported the rho coefficient and the P-value (P). 
 LDL HDL Total Cholesterol 
 Omnivores Vegetarians Omnivores Vegetarians Omnivores Vegetarians 
 rho P rho P rho P rho P rho P rho P 
SI 0.31 <0.001 0.21 0.06 0.23 <0.001 0.21 0.06 0.27 <0.001 0.26 0.02 
CA 0.34 <0.001 0.18 0.11 0.16 0.017 0.20 0.71 0.28 <0.001 0.24 0.03 
 
53 
 
Objective 3: Evaluation of the possible mechanism through which 
dietary micronutrients/diet can influence lipid levels, by studying G*E 
interactions 
Overall diet 
Table 12 presents the results of G*E interaction considering overall diet as 
“environment” and LDL as phenotype. 
It reports the number of SNPs tested for each gene, the most significant SNP 
(best SNP), the p-value of the best SNP and the Bonferroni threshold. 
Table 12: Results of G*E analysis, with environment as “no-restriction” or 
“vegetarian” diet 
Gene Nr. 
SNPs  
Phenotype Best SNP P-value Bonferroni 
threshold 
CYP7A1 35 LDL rs1125226 0.0024 0.00142 
INSIG2 47 LDL rs11679259 0.0004 0.00106 
PCSK9 48 LDL rs11206517 0.0005 0.00104 
LPA 84 LDL rs9365200 0.0005 0.00059 
 
CYP7A1 did not show any gene level significant interaction with vegetarian 
diet. The candidate SNP rs3808607 showed a borderline significant G*E 
association if considered alone (P= 0.049). 
For INSIG2 besides the best observed SNP (rs11679259) two other SNPs 
had a significant G*E interaction (rs17047718, rs17047731) and all are in 
Linkage Disequilibrium (LD). 
For PCSK9 two other SNPs beside the best observed SNP had a significant 
G*E interaction (rs12067569, rs505151) and all are in LD.  
For LPA only rs9365200 was above the Bonferroni corrected p-value. 
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We then analysed the effects of the genotypes at the significant SNPs 
identified in INSIG2, PCSK9 and LPA on LDL residuals, divided by dietary 
group (Table 13). 
Three SNPs in PCSK9 (rs11206517, rs12067569 and rs505151) showed a 
gene level significance interaction with the diet. Rs11206517 was previously 
associated with triglycerides level in Han population 70 and it is in strong 
LD with rs505151 (also reported as E670G), a SNP that has been repeatedly 
associated with a “gain of function” mutation of PCSK9, determining higher 
LDL cholesterol levels 71. Rs12067569 was previously associated with LDL 
levels in American Indians, and its mutation was associated with higher LDL 
72.  
Table 13 shows that for all the three SNPs of PCSK9, individuals 
homozygous for the wild type exposed to vegetarian diet have lower LDL 
residuals compared to those exposed to “no restriction” diet. On the contrary 
heterozygous individuals exposed to vegetarian diet have higher LDL 
compared to those exposed to “no restriction” diet. In our sample there are 
no homozygous individuals for the mutated type.  
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Table 13: For each SNP with a gene level significance are reported: LDL residuals in relation to the genotype, stratified per diet 
(mean; standard deviation=SD; number of individuals); Minor Allele Frequency (MAF), P of the G*E interaction and region. ** LD 
 
 LDL residuals: mean SD and (frequency) 
MAF 
P 
G*diet 
Region  No restriction Vegetarian 
SNP Homozygous  
Allele 2 
Heterozygous Homozygous 
Allele1 
Homozygous  
Allele 2 
Heterozygous Homozygous 
Allele1 
PCSK9 
rs11206517** 4.68 
SD 30.36 
(288) 
-2.65 
SD 50.30  
(20) 
- -13.07 
SD 24.28        
(110) 
25.83 
SD 55.75 
(6) 
- 0.03 0.0005214 intronic 
rs12067569 4.54 
SD 30.40         
(289) 
-0.84 
SD 51.01          
(19) 
- -13.07   
24.28         
(110) 
25.83 
SD 55.75           
(6) 
- 0.03 0.0009756 intronic 
rs505151** 4.54 
SD 30.40         
(289) 
-0.84 
SD 51.01          
(19) 
- -13.07 
SD 24.28        
(110) 
25.83 
SD 55.75        
(6) 
- 0.03 0.0009756 coding 
INSIG 
rs11679259** 5.98 
SD 31.59   
(279) 
9.37 
SD 23.54 
(27) 
-60 
SD 87.68 
(2) 
-12.91 
SD 26.02          
(99) 
0.125 
SD 36.25          
(16) 
-7 
SD 0 
(1) 
0.06 0.0004389 upstream  
rs17047718** 5.98 
SD 31.59   
(279) 
9.37 
SD 23.54 
(27) 
-60 
SD 87.68         
(2) 
-12.91 
SD 26.02          
(99) 
0.125 
SD 36.25          
(16) 
-7 
SD 0 
(1) 
0.06 0.0004389 upstream  
rs17047731** 5.98 
SD 31.59   
(279) 
9.37 
23.54 
(27) 
-60 
SD 87.68         
(2) 
-12.91 
SD 26.02          
(99) 
0.125 
SD 36.25          
(16) 
-7 
SD 0 
(1) 
0.06 0.0004389 upstream 
LPA 
rs9365200 0.99 
SD 32.60        
(131) 
3.94 
SD 29.04         
(134) 
14.84 
SD 36.84    
(43) 
4.067 
SD 33.068          
(45) 
13.60 
SD 22.64          
(62) 
28.56 
SD 21.37           
(9) 
0.34 0.0005231 intronic 
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Since rs505151 (also reported as EG70G) has been repeatedly associated 
with a “gain of function” mutation of PCSK9, determining higher LDL 
cholesterol levels, we evaluated the levels of cholesterol in relation to 
rs505151 genotypes (table 14).  
Table 14: Variations of cholesterol levels in relation to genotypes of rs505151. 
PCSK9 
 N LDL Total cholesterol HDL 
Rs 505151 (EG70G) 
AA 404 106.05 
(SD 53.68) 
170.66 
(SD 80.25) 
66.54 
(SD 30.22) 
GA 25 110.89 
(SD 68.92) 
181.8 
(SD 91.30) 
71.38 
(SD 36.88) 
 
As shown in table 14, individuals with the mutated genotype tend to have 
higher LDL, total cholesterol and HDL levels, although not statistically 
significant. 
One SNP (rs9365200) in LPA shows gene level significant interaction. Rs 
9365200 was never reported before. Two nearby SNPs are in strong LD with 
rs9365200, even if they are not significant for G*E interaction after Bonferroni 
correction (see Figure 8): rs9365201 and rs9347438. The latter has been 
reported in a study on coronary heart disease in Han Chines Population 73. 
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Figure 8: Regional plot of LPA genomic region. In purple it is represented the best 
SNP (rs9365200) 
Figure 9, graphically describes a typical G*E interaction. It presents LDL 
levels (Y axis) across the three genotypes of rs9365200 (LPA) in vegetarians 
and omnivores. 
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Figure 9: graphical representation of LDL levels (residuals, Y axis), in relation to the 
genotype at SNP rs9365200, of gene LPA (X axis) in individuals reporting “no 
restriction” (blue) and Vegetarian diet (pink). 
 
The graph suggests that in TT genotypes of rs9365200 a vegetarian diet is 
expected to have a much greater efficacy in reducing LDL levels that in CC 
genotypes. 
At the same time it could be speculated that in TT genotype a “no restriction 
diet” would increase LDL levels. 
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PON 1 
Table 15 presents significant G*E interactions for SNPs in PON1 and 
selected CVD biomarkers, considering anthocyanins and polyphenols intake 
as environment. 
A significant G*E interaction (Bonferroni threshold is p=0.0028) indicates that 
the association between the SNP and the phenotype varies in relation to the 
environment, so it is different in the low Vs high intake group.  
Two SNP (rs854549 and rs854552) in PON1 show significant interaction with 
anthocyanins in the association with HDL. Other two SNPs (rs854571 and 
rs854572) show significant interaction with polyphenols in the association 
with HDL. Significant interaction with anthocyanins was also observed for 
rs854551, in relation to AIP. While an additional interaction with polyphenols 
intake was observed in the association between rs3917477 and total 
cholesterol and polyphenols. 
For the 3 SNPs showing significant G*E interaction with anthocyanins intake 
and for the 3 SNPs showing significant G*E interaction with polyphenols we 
evaluated how the phenotype (i.e. lipid profile) varies in relation to the 
genotype in the environments considered. 
Figure 10 shows “the trend of lipid profiles across the three genotypes for 
each significant GxE SNP in low or high environment. In particular, in high 
anthocyanins intake, HDL concentration was higher in carriers of the major 
CC genotype for rs854549 (p-value=0.001, Beta= 4.7) and in the minor CC 
genotype for rs854552 (p-value =0.001, Beta=5.6). AIP was lower in minor 
AA carriers for rs854551 (p-value= 0.034, Beta=-0.07). Considering high 
polyphenols intake, HDL concentration was higher in minor TT carriers for 
rs854571 (p-value=0.026, Beta=3.92) and higher in minor CC compared to 
GG for rs854572 (p-value=0.025, Beta=3.94). Rs3917477 was not 
significantly associated to cholesterol in high polyphenols intake” 55. 
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Table 15: Results of G*E analysis, considering anthocyanins and polyphenols intake environments. For each SNP of PON1 is reported 
the p-value for the interaction for selected phenotypes (HDL, LDL, TC=Cholesterol, TG=Triglycerides and AIP phenotypes). In bold are 
indicated significant valued (From Rizzi et al, 2016) 55 
  Anthocyanins intake Polyphenols intake 
SNP HDL LDL TC TG AIP HDL LDL TC TG AIP 
rs854549 0.0008 0.3941 0.1031 0.6548 0.1787 0.0998 0.5160 0.2006 0.5240 0.9975 
rs3735590 0.3448 0.1405 0.0397 0.0622 0.3134 0.2444 0.0866 0.0303 0.1277 0.2865 
rs854551 0.0042 0.6413 0.8251 0.0103 0.0022 0.0206 0.0634 0.0575 0.0064 0.0041 
rs854552 0.0010 0.6538 0.3149 0.1498 0.0177 0.0071 0.4599 0.6442 0.1186 0.0493 
rs3917477 0.9098 0.0364 0.0437 0.4110 0.6409 0.0701 0.0674 0.0026 0.0544 0.4517 
rs854571 0.1042 0.3670 0.1272 0.3527 0.9355 0.0021 0.1417 0.0067 0.4772 0.4889 
rs854572 0.0087 0.8026 0.2546 0.6123 0.3915 0.0020 0.5219 0.1108 0.8518 0.2163 
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Figure 10: “Phenotypes distribution relative to genotypes at rs854549 (a), rs854551 (b), rs854552 (c), rs3917477 (d), rs854571 (e) and 
rs854572 (f) according to anthocyanins and polyphenols intakes. Y axis reports the residuals for each phenotype (HDL, AIP and 
cholesterol). The bars summarize the distribution as mean and standard errors. For each bar, the numbers of individuals per genotype 
are indicated. PGxE denotes the SNP x environment interaction analysis comparing high and low intake both for anthocyanins (a, b, c) 
and polyphenols (d, e, f).P indicates the multivariate linear regression analysis comparing genotypes in each environment subgroup 
(low/high); Beta coefficients refer to minor alleles”. (From Rizzi et al, 2016) 55 
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Objective 4 - Development of tools for personalized nutrition in CVD 
prevention 
The DMS web-based platform combines validated tools for nutrigenomic 
research. It provides a configurable CRF to collect patient’s data (i.e. 
personal medical history, physical, laboratory examination, therapies, etc.) 
and dietary habits, through interviews and food frequency questionnaires. 
The tool, to support data collection during dietary interviews, includes the 
possibility to select foods and recipes for each meal. The software then 
combines input data from dietary interviews and food nutrients composition, 
from validated food databases, and calculates macro and micronutrients 
intakes (e.g. daily, monthly etc.).  
CRF template can be shared between different research centres, in case of 
multicenter studies, and used for data collection, ensuring anonymous data 
processing. The web-based platform in fact stores only patients’ unique 
identifiers and does not contain patients’ personal identification information. 
Also, the platform manages the direct exchange of data with the mHealth 
app, that can be used by the patient to upload dietary and lifestyle information 
(e.g. Diaries). 
The following figure presents the working environment of the web platform 
and the CRF section dedicated to the collection of dietary information. 
 
63 
 
 
 
Figure 11: “A. The work environment of the web-based platform in a single operative 
unit. B. The CRF allows easy data entry by the selection of a food name automatically 
mapping the selected food to its code in the food database” (From Conti et al, 2015)74 
 
Genotypic data are managed exclusively by the healthcare professional and 
can be uploaded from PED and MAP files, which constitute standard formats 
for genomic analysis software.  
This platform was used to collect information from more than 500 volunteers 
participating to ATHENA project.  
Both the platform and the mHealth app can provide access to a semi-
automatic DSS that process data and provide suggestions considering: a) 
phenotype, b) nutritional habits, c) genetic profile, namely mutations that 
were associated to G*E interaction with the diet. The logic behind the DSS 
prioritize the information as indicated in Figure 12, below. 
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Figure 12: Diagram of the semi-automatic DSS 
The genetic information that is processed by the DSS search engine needs 
to be preselected and presented in a tabular format in which they are related 
to DSS rules. 
All suggestions provided by the DSS need to be validated by healthcare 
professionals, before being displayed in the patient’s mHealth app. 
The DMS system was reengineered after the project ATHENA. The current 
version, named ePhood, is used in research context, to collect data from 
nutrition and nutrigenomic studies. The mHealth app is provided to subjects 
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enrolled in observational studies and is used to collect/track their diet and 
lifestyle. 
The integration of CVD risk scores with dietary guidelines (e.g. LARN for 
Italy) can provide additional information to the healthcare professional and to 
health concerned citizens.  
To overcome limitations typically affecting the usability of mHealth App in a 
healthcare context, we designed a platform in agreement with standards-
based architectures implementing bi-directional communication between 
mHealth apps and electronic health records, ensuring secure data exchange 
and technological and semantic interoperability. 
Early adopters are suggesting new functionalities and upgrades to the 
system. In particular we are focusing on developing functionalities to make 
mHealth more user-friendly. 
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5 DISCUSSION 
 
Objective 1: Evaluation of the association between well-established 
risk factors of CVD Vs dietary micronutrients/dietary patterns 
In the context of the ATHENA project we conducted a nutritional and 
nutrigenomic study to analyze the effects of vegetarian diet and of dietary 
anthocyanins and polyphenols on CVD risk factors.  
In our sample of apparently healthy volunteers, the percentage of 
vegetarians (26.4%) is probably higher than the percentage in the general 
population of Milano, but we cannot rely on exact statistics. However Milano 
is known to be the city where vegetarianism is more popular in Lombardy 
region, and Lombardy is the Italian region with the higher representativeness 
of vegetarians (18% of the population) 75. 
The differences observed in dietary macronutrients and micronutrients 
composition between omnivores and vegetarians are expected. The average 
anthocyanin consumption in our sample (22.80 mg/day in omnivores and 
40.57 in vegetarians) is slightly lower than the one estimated in a study 
conducted in Varese in the context of the EPIC investigation (55.48 mg/day 
in men and 40 in women) 76. The average polyphenols intake in our sample 
(1,016.59 mg/day in omnivores and 1,582.99 mg/day in vegetarians) is also 
slightly lower than the one estimated in Varese by EPIC (1,300 mg/day for 
women and 1,500 in men). However EPIC and ATHENA adopted different 
anthocyanin and polyphenols dosage methods making comparison very 
difficult 77. 
The observation that all CVD risk factors are decreased in vegetarians 
compared to omnivores (i.e. SBP, total cholesterol, LDL, BMI, Waist 
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circumference) except for HDL, triglycerides and IMT is in agreement with 
previous studies 78-79. 
Lower LDL and total cholesterol levels observed in vegetarians could be 
related to the competitive effect of plant sterols, limiting cholesterol 
absorption, to low cholesterol and high fibre intake associated to vegetarian 
diets and/or to differences in the cholesterol synthesis/turnover.  
A high adherence to Mediterranean diet is associated with reduced BMI, 
waist circumference and blood pressure, and with higher HDL levels, but not 
with changes in LDL and total cholesterol levels.  
High intake of dietary polyphenols is inversely associated with BMI, waist 
circumference and blood pressure. A recent review supports the efficacy of 
polyphenols in reducing BMI and central obesity in patients with Metabolic 
Syndrome. However it shows that the result are largely dependent on the 
type of polyphenols considered. Almost all interventional studies with tea 
(mainly green tea) as source of polyphenols (catechins) showed a significant 
decrease of the BMI, while for other foods the results are less consistent. On 
the contrary the effect on blood pressure reduction was stronger for cocoa 
and olive oil 80. 
Individuals consuming high amounts of anthocyanins do not show protective 
effects on the CVD risk parameters considered. The effect of anthocyanins 
on blood pressure has been recently questioned. A meta-analysis including 
427 patients from 6 interventional trials, administering anthocyanins 
supplements (from 162 mg/day to 640 mg/day), indicated that anthocyanins 
do not decrease blood pressure 81. 
However it could be postulated that in our population the consumption of 
anthocyanins is below the efficacy threshold, which has never been 
established in pharmacokinetic/pharmacodynamics studies. In facts, studies 
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reporting effects of anthocyanins on LDL and HDL plasma concentrations 
are interventional trials, using anthocyanins extracts or pure anthocyanins 
82. 
Considering the observational nature of the study, it may be difficult to dissect 
the specific contribution of diet on the reduction of the risk factors considered, 
since dietary habits are often associated with other lifestyle behaviors. For 
example, Serdula et al have shown a positive correlation between the intake 
of fruit and vegetables with other negative habits: fruit and vegetables 
consumption was lower in sedentary persons, heavy smokers and drinkers 
83. 
 
Objective 2: Evaluation of possible mechanism of action of dietary 
micronutrients/diet on lipid levels, by studying sterols implicated in 
cholesterol homeostasis  
Mean campesterol levels in omnivores and vegetarians in our sample, 
respectively 9,999.54 µl/L (± 4,624.66) and 11,757.9 (± 3,929.48), are higher 
than in previously published studies. Reported mean campesterol levels 
varies from 5,400 µl/L ± 2500 28 to 2,355 in omnivores and from 3,500 µl/L 
(±1,300) to 3,780 µl/L 29 in vegetarians. In our sample also mean sitosterol 
levels, respectively 5,026.68 µl/L (± 2,631.30) in omnivores and 6,398.51 
(±2,400.42) in vegetarians are higher than previously described. Reported 
mean sitosterol levels varies from 3,500 µl/L (± 1,300) 28 to 1,246 µl/L in 
omnivores and 3,310 µl/L to 2,500 µl/L (±1,300) 29 in vegetarians. It should 
be noted however that such results are likely to be related to different 
methodologies/instruments used in the different laboratories. The internal 
validity of our results is supported by fact that all studies observe similar 
campesterol: sitosterol ratios. In addition none of those studies was 
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conducted in Italy, and differences in dietary habits may vary across 
populations. 
Sitosterol and campesterol ratios over total cholesterol are higher in 
vegetarians compared to omnivores. The absolute value of sitosterol is also 
significantly higher in vegetarians compared to omnivores while there is no 
difference in the absolute value of campesterol. The stronger association of 
sitosterol with diet, compared to campesterol, is supported by a recent review 
indicating that sitosterols plasma concentrations increase in dose- 
dependent manner as sitosterol dietary intake increases, while no dose-
dependent association is observed for campesterol 84. 
Interestingly, in vegetarians the observed increase in phytosterols is not 
correlated with an increase in LDL or in HDL, whereas such correlation was 
statistically significant in omnivores. This might suggest that the increase in 
phytosterols in vegetarians mainly reflects an increased phytosterol 
consumption with the diet, not an increased cholesterol absorption, as 
previously suggested by Sarkinnen et al 27. 
For what concerns markers of de novo cholesterol synthesis: we observed 
lower concentrations of plasma lathosterol in vegetarians, in subjects with 
high polyphenols intake, in subject with high anthocyanins intake and in 
subjects with high adherence to Mediterranean diet, but only for the latter 
group the association was statistically significant. This finding is 
accompanied by an increase in desmosterol concentration in vegetarians 
and in subjects with high adherence to Mediterranean diet, which is 
statistically significant only for vegetarians. Such variations, together, 
determine differences in lathosterol: desmosterol ratio, which is significant 
between vegetarias and ominivores and also between group of high and low 
adherence to Mediterranean diet. This might suggest that diet has a different 
effect on the two pathways of cholesterol synthesis. The increase in 
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desmosterol could even be beneficial, given its effect in stimulating 
cholesterol efflux 37. 
The effects of plants-rich diets on lathosterol levels is inconsistent across 
studies. In 1998, Sarkinnen et al reported an increase of lathosterol in 
individuals receiving diets characterized by low cholesterol/high 
polyunsaturated fatty acids intake, and suggested that this finding could be 
related to a feedback reaction, in relation to reduced dietary cholesterol 
absorption 27. However most recent studies on vegetarians or vegans 
indicate a reduction of lathosterol in subjects receiving plants-rich diets 28. 
In the present study, we observe an increase in all the considered oxysterols 
(24-OHC, 25-OHC and 27-OHC) over total cholesterol ratios in vegetarians. 
However the result for 24-OHC and 25-OHC, could be due to a distortion due 
to the lower total cholesterol levels observed in vegetarians. In fact, if we 
consider the absolute values of these sterols there are no significant 
differences among groups. 
The most significant result is recorded for 27-OHC. Its ratio over total 
cholesterol is significantly higher in vegetarians, in subjects with high 
polyphenols intake, and in subjects with high adherence to Mediterranean 
diet. Its absolute values are also significantly higher in vegetarians and in 
subjects with high adherence to Mediterranean diet. 
Interestingly, 27-OHC plasma concentrations are increased in vegetarians 
despite the fact that these individuals have lower total cholesterol and lower 
LDL. In addition, in omnivores 27-OHC is inversely correlated with HDL 
levels as expected, being a compensatory mechanism for cholesterol 
elimination from tissues 41 when the reverse cholesterol mechanism is not 
sufficient, while in vegetarians 27-OHC is not correlated with HDL levels.  
71 
 
This findings could suggest that cholesterol turnover is enhanced in 
vegetarians. Clearance through 27-OHC could contribute to the decreased 
cholesterol levels observed in individuals consuming plats-rich diets, even if 
changes on HDL levels are not evident. 
Our results on 27-OHC suggest a new possible mechanism through which 
plant-rich diets reduce total cholesterol and LDL levels: by means of 
mechanisms that enhance cholesterol turnover and removal from peripheral 
tissues. 
 
Objective 3: Evaluation of the possible mechanism through which 
dietary micronutrients/diet can influence lipid levels, studying G*E 
interactions 
We observed that SNPs in genes PCSK9, LPA and INSIG2 modulate the 
effect of overall diet (omnivore Vs vegetarian) on LDL levels. 
PCSK 9 gene encodes for protein convertase subtilisin/kexin type 9, a 
protease that regulates cholesterol metabolism by promoting LDL-receptor 
degradation, thus rendering it unavailable and leading to elevated levels of 
circulating LDL. Overfunctional mutations (“gain of function mutations”), such 
as those reported in familial hypercholesterolemia are associated with high 
serum LDL. Several studies are currently studying PCSK9 as a potential 
candidate for cholesterol lowering therapies. 
Serum PCSK9 concentrations appear to be influenced by dietary nutrients: 
both PUFA and MUFA-enriched diets decrease serum PCSK9 
concentrations; increased dietary cholesterol downregulates hepatic PCSK9 
mRNA expression; dietary fructose may increase the concentration of serum 
PCSK9 62. The following figure summarizes the findings related to the 
nutritional control of PCSK9. 
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Figure 13: Mechanisms associated with nutrient regulation of hepatic and serum 
PCSK9 (From Krysa et al, 2017) 62 
 
PCSK9 showed a G*E interaction, with overall diet. The three SNPs that 
show gene level significant interaction are in LD and one of them (rs505151) 
is a strong candidate SNP for LDL, reported in several populations 71. In 
our sample the variation in rs505151 was associated with increased LDL 
levels, as reported in previous studies (“gain of function mutation”). In our 
sample there are no homozygous individuals for the mutated genotype, in 
line with the low MAF of this SNP. 
A recent study revealed signatures of positive selection in the gain of function 
mutation of rs505151. However the forces driving this selection remain 
unclear 85. 
The effect of diet on LDL is modulated by rs505151, in particular vegetarian 
diet is beneficial for subjects homozygous for the wild type allele, but not for 
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those carrying the mutated allele. In fact, in individuals with the wild type 
genotype vegetarian diet lowers LDL compared to omnivores, whereas 
individuals carrying the mutated genotype behave in the opposite way, 
showing an increase of LDL residuals in vegetarians. Our observation could 
be associated with higher dietary fructose intake, in the vegetarians, which 
was previously associated with increased plasma PCSK9 concentrations 
and with higher cholesterol intake in omnivores which was associated with a 
downregulation of hepatic PCSK9 62. This G*E interaction could also be 
associated with an increased activity of PCSK9 in individuals that carry a 
mutation that induces a gain of function. However PCSK9 is regulated by 
several nutritional factors and it is not clear how they exert their functions or 
how they interact. 
LPA showed to modify the effect of “overall” diet on LDL. In fact, LDL 
changes in relation to diet were very modest in individuals homozygous for 
the wild type genotype (similar LDL levels in the two dietary groups) while 
vegetarian diet exerted a marked beneficial effect in individuals carrying the 
mutated genotype (stronger in homozygous). However it is difficult to 
understand the biological plausibility behind this observation, since it was 
observed only in one SNP (rs9365200) (i.e. the only SNP reaching a gene 
level significance).  
LPA gene encodes an apolipoprotein that is part of lipoprotein A (Lp(a)). 
Lp(a) is a plasma lipoprotein, synthesized by the liver, containing a LDL 
particle, one molecule of apolipoprotein B-100 and apolipoprotein (a). 
Elevated plasma levels of Lp(a) are independent risk factors for 
atherosclerosis and CVD. It is reported that approximately 30% of variance 
in Lp(a) levels is determined by the kringle IV type 2 (KIV-2) copy number 
variant in LPA, which encode variability in the size of apolipoprotein(a). The 
rs10455872 SNP in LPA was found associated with LDL response to statin 
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treatment in two GWAS 86-87. The possible mechanism of action is not 
elucidated. The Omni Heart Trial studied the effects of three different 
“healthy” diets (i.e. a protein-rich diet, an unsaturated fat-rich diet and a 
carbohydrate-rich diet) on Lp (a) levels. All diets were reduced in saturated 
fat, cholesterol, and sodium, and rich in fruits, vegetables, fish, potassium, 
and other minerals. Compared with baseline, all “healthy” dietary 
interventions increased mean Lp(a) plasma levels. Among dietary 
interventions, the unsaturated fat-rich diet increased Lp(a) plasma levels less 
than the protein-rich diet and the carbohydrate-rich diet 88. 
 
INSIG2 gene encodes the insulin-induced gene 2, a endoplasmic reticulum 
protein that binds to oxysterols. In 2006, a SNP in the promoter region of 
INSIG2 was associated to obesity 89, but only in 2013 it was associated 
with total cholesterol and LDL 58. The association of INSIG2 with LDL was 
then confirmed by a fine-mapping study and by exome sequencing 90.  
Binding oxysterols it inhibits the activity of sterol regulatory element binding 
proteins (SREBP), thus “preventing the transcription of genes involved in 
both cholesterol uptake and synthesis. Additionally, INSIG2 binds HMG-CoA 
reductase, the rate-limiting enzyme in endogenous cholesterol synthesis, 
and targets HMG-CoA reductase for degradation, further slowing cholesterol 
synthesis” 91. 
In an observational study conducted on Samoans, studying G*E interactions, 
considering different type of diets classified as “modern” (western diet), 
“traditional 1” and “traditional 2”, SNP rs9308762 showed an interaction with 
the type of diet, with homozygotes for the C allele resulting to be more 
susceptible to the increase in blood triglycerides associated to modern 
dietary pattern. 
In a trial on obese children undergoing a 1 year intervention program which 
promoted healthy diet (plus other interventions), children homozygous for the 
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C allele in the rs7566605 SNP of INSIG2 lost significantly less weight than 
children carrying the G allele. Unfortunately the study does not report the 
effect of the intervention program on lipid profile, in relation to genotype 92. 
In another study evaluating INSIG1 haplotypes and progression of 
atherosclerosis in women, no G*E association with diet was observed 93. 
 
 
Figure 14: Schematic representation of the biological functions of INSIG2 (insulin-
induced gene 2) in relation to cellular cholesterol metabolism. When there is abundant 
sterol in the endoplasmic reticulum (ER) INSIG undergoes conformational changes and 
prevents SREBP transport from ER to Golgi, which reduces the production of lipid in 
cells (From Kalatarian et al, 2014) 93. 
The significant G*E interaction shown for INSIG2 gene is difficult to interpret 
since: 
 a very limited number of individuals homozygous for the minor allele 
were available (2 in the omnivorous group; 1 in the vegetarian group); 
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 previous published nutrigenomic studies concentrated on BMI and 
triglycerides, as they were performed before that evidences on the 
association of INSIG2 with LDL and total cholesterol were available; 
 two of the SNPs showing gene level significance, rs17047718 and 
rs17047731, were previously associated with glucose homeostasis 
traits, in the Hispanics of the Insulin Resistance Atherosclerosis 
Family Study (IRASFS) 94. Reference LDL values for the different 
genotypes of the two significant SNPs are not published. 
However it will be interesting to assess G*E interactions considering 
oxysterols (24-OH cholesterol, 25–OH cholesterol, 27-OH cholesterol) as 
phenotypes. In facts INSIGs are oxysterol-binding proteins and have been 
shown to play a role in the effect of oxysterols as feedback regulators of 
cholesterol homeostasis. In particular 25-OH cholesterol binds to INSIG2 and 
induces the binding of INSIG1 to SCAP, and blocking SREBPs 95. 
Our result indicate that vegetarian diet does not show significant gene level 
interaction when considering CYP7A1 and LDL. However we confirm the 
SNP level G*E significance in SNP rs3808607, which was reported in several 
studies. 
CYP7A1 gene encodes cholesterol 7-alpha-hydroxylase associated to 
cholesterol excretion, regulating a rate limiting step in the bile acid synthesis, 
which is the primary mechanism for the removal of cholesterol from the body. 
Polymorphisms in the promoter of this gene are associated with defects in 
bile acid synthesis.  
In the MONICA cohort, that considered as protective diet 8 years of low 
intake of red meat, animal fat and eggs, carriers of the SNP rs3808607-C 
allele showed a greater reduction in plasma total cholesterol levels than the 
AC and AA 96. Several interventional trials confirmed these results. 
Abdullah et al 53 reports that: 1) in a study that employed a Mediterranean 
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style diet, carriers of the CYP7A1 SNP rs3808607 C allele showed greater 
reductions in plasma total cholesterol levels than the AA homozygotes; 2) in 
another trial with crossover design, SNP rs3808607 CC homozygotes 
showed higher serum total cholesterol and higher LDL levels after 3 weeks 
of a high-fat (40% energy) compared with a low-fat (22% energy) diet; 3) in 
a study considering 174 normolipidemic subjects, the presence of the C 
allele, when compared with the AA genotype, was associated with about 63% 
higher plasma total cholesterol concentrations, when the subjects were 
exposed to an increased intake of dietary cholesterol. Another randomized 
trial, investigating the impact of dairy products consumption on cholesterol 
levels, showed that, after the intervention, total cholesterol concentrations 
were higher among carriers of the CYP7A1 rs3808607 C allele, whereas LDL 
concentrations were higher among rs3808607 heterozygous in comparison 
to AA homozygotes 97. 
It would be interesting to conduct further analysis considering oxysterols as 
phenotypes, as they are markers of cholesterol turnover, and are related to 
the activity of CYP7A1 in the synthesis of bile acids. 
 
We identified 5 independent SNPs in PON1 gene (rs854549, rs854551, 
rs854552, rs854571, rs854572) showing a gene level significant interaction 
between the selected CVD risk factors and anthocyanins/polyphenols intake. 
PON1 encodes for paraoxonase 1 (PON1) enzyme, a glycoprotein which 
associates with HDL in the circulation. PON1 is a primary determinant of the 
antioxidant and anti-inflammatory activity of HDL, promoting the HDL-
mediated macrophage cholesterol efflux, in the “Reverse Cholesterol 
transport”. PON1 activity is genetically regulated and different SNPs in PON1 
gene were associated to the strength of arylesterase and paraoxanase 
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activities 98-99. In addition several external factors are known to modulate 
PON1 activity and HDL (e.g. dietary factors, lifestyle, statins, etc.). 
Without taking in consideration PON1 genetics we could not observe any 
association between high and low antioxidant intakes and target phenotypes, 
in line with previous interventional studies that showed discordant results on 
the effect of anthocyanins.  
In individuals reporting high anthocyanins consumption, “carriers of the C 
protective allele at rs854549 showed an increase in HDL levels of 4.7 mg/dl 
while carriers of the C protective allele at rs854552 showed an increase of 
5.6 mg/ dl. In individuals reporting high polyphenols consumption, HDL levels 
were 3.92 mg/dl higher in T carriers for rs854571 and 3.94 mg/dl higher in C 
carriers for rs854572”. …. “AIP was lower in A carriers for rs854551, with a 
decrease of 0.07 in high anthocyanins intake” 55.  
Rs854549 is a 3′flanking variant that has been repeatedly reported as 
modulator of PON1 activities 100-101. Rs854552 was reported as 
significantly associated to paraoxonase activity of PON1 [101]. 
Rs854571 and rs854572 map in the promoter region of PON1 gene and have 
been independently associated to a significant change in PON1 expression 
levels in human hepatoma cell line HepG2 [102]. In particular for rs854571 it 
was reported that T allele of rs854571 determined a significant increase in 
activity of PON1 [103].  
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Objective 4 - Development of tools for personalized nutrition in CVD 
prevention 
A number of factors contribute to the inter-individual variability observed in 
responses to diet, including gender, age, metabolic status, physical activity, 
genetic background, microbiome as well as environmental exposures.  
Some of these factors (e.g. age, gender, BMI) are routinely considered when 
a nutritionist develop personalised nutritional recommendations; however 
more complex factors such as genomics, microbiome and environmental 
exposures are not taken into account.  
This simplistic approach is much more evident when considering CVD risk 
scores. It is amazing that despite the strong evidences available on the 
protective effects of “healthy diets” on CVD risk factors, available risk scores 
do not even take in consideration dietary behaviours.  
As suggested by Lampe et al, the best way to guide personalized dietary 
interventions would be to develop a thorough understanding of the metabolic 
changes occurring in relation to dietary factors under different conditions, 
adopting a “multi-omics” approach [104]. 
Such degree of knowledge is not currently available, but the use of genetic 
tests to evaluate an individual response to a wide variety of nutrients is 
becoming more and more common, indicating that at least a health 
conscious niche of the population is interested on this approach. 
The integration of personalized dietary suggestions, based on validated G*E 
interactions seems promising. In fact, the magnitude of the effects observed 
in G*diet interactions is much higher than those observed in genetic studies 
[53], indicating this approach could be useful for stratified prevention. 
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The DMS addressed these gaps and proposed additional features that make 
it suitable to be used as a tool in nutritional and nutrigenomic studies. It can 
be further implemented to support tailored prevention.  
As previously discussed, there is urgent need of increasing the efficacy of 
existing prevention programmes, and several studied indicate that concerted 
actions (programmes targeting different contexts and using different tools) 
are more likely to be successful. mHealth could be one of the tools used in a 
stratified prevention programme, to engage patients. In this context a 
mHealth app that is used by the patient in agreement/communication with 
his/her healthcare provider seems an ideal solution. In fact, from one side 
data gathered by the patient can be transferred to electronic medical records 
and become available to the healthcare provider when needed, and from the 
other hand patients/citizens receive information validated by health 
professionals. The DSS, taking into account research data and updated 
guidelines, elaborates dietary and lifestyle suggestions by mean of inferential 
algorithms built to recreate the complexity behind the multiple effects and 
interactions between nutrients and cholesterol metabolism, considering also 
evidences from “omics”, when available. The choice of using a semi-
automatic DSS increases the trust of healthcare providers and facilitate the 
adoption of the tool. 
The mHealth solution will be further implemented to take into consideration 
user’s behavioral patterns and machine learning behavioral analysis. 
Moreover, it will guarantee a smart and quick data entry (e.g. photo 
capturing). 
Strengths and Limitation of the study 
The cross sectional study conducted in Milano, in the context of ATHENA 
project, offers the possibility of studying the effects of long term exposure to 
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vegetarian diet on a number of established risk factors of atherosclerosis, 
since the study population (healthy volunteers) involved both omnivores and 
vegetarians (i.e. lacto-ovo and vegans). 
ATHENA has some intrinsic limitations which are characteristic of nutritional 
studies. In facts it is widely recognised that available methodologies cannot 
capture precisely the dietary intake. 
On the other hand, the finding observed in this type of studies, conducted in 
an ecological context are not due by artefactual conditions, typically 
observed in intervention trials. As suggested by Azqueta et, “when 
investigating the role of phytochemicals in normal human nutrition, the aim 
should always be to study concentrations close to those likely to be present 
in humans as a result of dietary intake” [105]. 
Typically interventional trials use very high concentration of bioactive 
components. For example, studies used to define the efficacy of plant sterols 
interventions in reducing blood cholesterol concluded that 2mg/day of plan 
sterols are effective, even if this amount is more than 10 times higher than 
the amount normally introduced with the diet, implicitly paving the way for 
nutraceutical interventions. 
Our healthy and relatively young population may not be appropriate to detect 
endpoints such as IMT, which indicates a subclinical atherosclerosis. 
Nutrigenomic is a young discipline and our results, as most of the results 
published in this field, warrant validation.  
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6 CONCLUSIONS 
Our study brings new evidences to elucidate possible molecular mechanisms 
underlying inter-individual variability in the susceptibility to diet induced 
changes in cholesterol levels and to elucidate effects of vegetable rich diets 
in modulating cholesterol homeostasis. 
Our results on 27-OHC suggest a new possible role of plants-rich diets in 
reducing total cholesterol and LDL levels, through mechanisms that enhance 
cholesterol turnover and removal from peripheral tissues. 
Results of PCSK9 interaction with vegetarian diet warrant replication, as one 
of the SNPs found to modulate the effects of diet on LDL levels, is a well-
known “gain of function” mutation.  
This study is the first exploring G*E interactions considering anthocyanins 
and polyphenols as “environment”. Different SNPs in PON1 were found to 
modulate the effects of anthocyanins/polyphenols on cholesterol levels. 
These results need validation in an independent sample. 
In addition, in the context of ATHENA we implemented a platform for 
nutritional and nutrigenomic studies including a mHealth app to collect 
dietary and lifestyle data. The use of mHealth tools is synergic to the 
development of personalized/stratified nutrition interventions, since they 
facilitate dietary and lifestyle data collection. The use of a DSS that through 
machine learning and cognitive computing techniques process data and 
develop inferences is needed to understand the complex effects of dietary 
components on the homeostasis. Algorithms and risk prediction models can 
be refined periodically to include the best available research evidences thus 
fastening the introduction of personalized nutrition, which is a promising, but 
young field of investigation. 
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